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ABSTRACT OF DISSERTATION 
 
 
 
CRITICAL EVENTS IN HUMAN METAPNEUMOVIRUS INFECTION:  FROM ENTRY TO 
EGRESS 
 
 
Human metapneumovirus (HMPV) is a respiratory pathogen in Paramyxovirus family 
that demonstrates extremely high morbidity in the population, with most individuals 
having been infected by the age of five.  Despite the prevalence of this negative-sense 
RNA virus in the population for decades, it was only identified in 2001.  As such, there is 
currently no specific treatment for HMPV and the potentially severe consequences of  
infection for elderly and immunocompromised individuals and particularly infants make 
development of antivirals targeting HMPV of high significance.  HMPV constitutes a 
quarter of all respiratory hospitalizations among infants, placing it second only to RSV, 
in addition to becoming a greater concern in concentrated populations of seniors.  For 
these susceptible populations, the consequences of infection have a much greater 
probability of leading to pneumonia, bronchiolitis and even death. 
 
These studies investigate events throughout the infectious cycle of HMPV.  They 
describe specific amino acids that modulate the triggering of viral fusion activity in 
response to low pH. They also include a report on the dynamic and variable control 
exercised over gene transcription by viral promoters.  Finally, the interplay between viral 
nonstructural proteins and their distinct roles in both replication and assembly are 
examined.  Ultimately, this work seeks to elucidate the goings-on within an HMPV-
infected cell at multiple points throughout the process. 
  
Keywords: Human metapneumovirus (HMPV), RNA-dependent RNA polymerase 
(RdRp), phosphoprotein, nucleocapsid, minireplicon 
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Chapter I:  Introduction 
 
Subsection I:  General Overview 
 
Paramyxoviruses are a diverse family of viruses that infect a range of host species and 
include many noteworthy human pathogens among their number.  Some of the more 
well-characterized members of the family include measles and mumps viruses; 
additionally, emerging viruses are prevalent among paramyxoviruses, including the 
zoonotic Hendra and Nipah viruses, which feature alarmingly high levels of mortality in 
their contained outbreaks [1].  All paramyxoviruses display several common 
characteristics—their virions (infectious particles) are enveloped by a host cell-derived 
phospholipid membrane bilayer.   They each encode relatively few gene products, no 
more than 10 for any known member of the family, in a non-segmented negative-sense 
RNA genome, and all exhibit pleimorphism with regard to the size and shape of their 
infectious particles [2].  Paramyxoviruses are members of the phylogenetic order 
Mononegavirales due to their genomes, and phylogenetic analysis demonstrates the 
similarity of this viral family to some of the most dangerous pathogens known, including 
the filoviruses, such as Ebola and Marburg viruses and rhabdoviruses, including rabies 
(Figure 1.1) [3-8].   
 
The focus of this research, however, features one particular paramyxovirus.  This 
pathogen, human metapneumovirus (HMPV), is symptomatically similar to other 
respiratory agents, such as influenza and human respiratory syncytial virus (hRSV) with a 
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tissue tropism throughout the human airway.  Unlike these other pathogens, however, 
HMPV has only recently been characterized, being first isolated in 2001 in the 
Netherlands.  Clinical samples from children presenting respiratory symptoms from an 
unidentified etiological agent were obtained and the virus isolated.  Upon studying the 
characteristics of the virus, including the contents of its genome, homology to avian 
metapneumovirus led to the categorization of this agent as the second isolated 
metapneumovirus—HMPV.  The researchers then were able to test children, first 
throughout the Netherlands and subsequently worldwide, and found that nearly all 
individuals over the age of five presented antibodies against this agent.  Testing stored 
clinical samples also allowed for the determination that HMPV had been present in the 
population for at least fifty years prior to its characterization. [9].   
 
HMPV has since been shown to be the second leading causative agent for respiratory-
related hospitalizations for children under the age of five, trailing only the closely-related 
hRSV [10].  Further epidemiological studies have also revealed that HMPV accounts for 
6-11% of respiratory tract infections in children under the age of five and that  the 
percentage of HMPV-positive cases was significantly greater (up to 25%) for children 
under the age of two [11].  Additionally, due to the existence of several phylogenetic 
groupings or clades, to which unique immunological responses may be triggered, HMPV 
is a great threat later in life to large populations of individuals, such as elderly and 
immunocompromised persons as well as those with cardiopulmonary disease [12].  All of 
these groups, in addition to infants and young children,  may suffer more severe 
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complications as result of HMPV infection also including bronchiolitis, pneumonia and 
death [13-14].   
 
As dire as these statistics may seem, they may, in fact, underestimate HMPV cases, as 
serum etiological assays are often not performed to definitively identify an agent.  This 
potential underrepresentation is due to similar symptomology to other respiratory 
pathogens for which—as in the case of HMPV—there is no specific course of treatment.  
Several proposed therapies have been tested, such as prophylactic antibody treatment, 
which is the only FDA-approved treatment for hRSV, but the efficacy of this therapy is 
unclear in the case of HMPV infection [15-17].   
 
Another proposed treatment is the general antiviral compound ribavirin, an oral 
nucleoside analog that induces errors in the rapidly synthesized RNA genomes of the 
infecting agent, and there have been reports of success with this treatment [18].  This 
treatment would be extremely efficacious in treating these agents as their replicative 
cycle is dependent on RNA to the exclusion of DNA.  However, the drug is also a 
potential teratogen, and recent evidence casts doubt on its efficacy in severe HMPV 
infection [19].  There are also other proposed treatments for which it is too premature to 
determine the clinical relevance [20].  The current state of clinically available treatments 
for HMPV underscores the desperate need for greater understanding of novel aspects of 
this recently characterized pathogen’s infectious cycle as an initial step towards the 
develop of specific treatments for the afflicted and at-risk populations.  
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As this virus has only recently been identified, there is still much that is simply not yet 
understood about its function in host cells.  In fact, much of what is accepted by the field 
on HMPV comes from correlations drawn to similar viruses, despite the observation that 
phylogenetic nuances tend to make such generalizations somewhat specious.  It has been 
specifically determined that the HMPV virion contains a ribonucleoprotein (RNP) core 
composed of the negative-sense genomic RNA encapsidated by the nucleocapsid protein 
(N), which is packaged with the RNA-dependent RNA polymerase (RdRp) and the 
matrix protein (M), which is thought to be involved in maintaining virion structure [21].   
Surrounding the outside of this core is a host-derived phospholipid membrane bilayer 
known as an envelope with fusion (F), attachment (G) and small hydrophobic (SH) 
glycoproteins decorating the surface (Figure 1.2) [22]. 
 
These early observations have served as the basis for countless subsequent studies of 
HMPV, and the knowledge base on this pathogen has steadily grown.  The field now has 
a firm grasp on numerous characteristics of the infectious cycle.  A number of studies 
have focused on the entry mechanism of the virus [23-28].  There have also been a small 
number of investigations into the dynamics of the HMPV-encoded proteins responsible 
for genome replication as well as a few studies on assembly of progeny viruses [29-30].  
The overall goal of my thesis work has been to harmonize the findings of studies in all 
these areas of HMPV pathogenesis in order to shed light on some of the most critical 
events at several stages of infection from the triggering of membrane fusion and entry to 
viral RNA synthesis and assembly.  
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Subsection II:  HMPV Fusion and Entry 
 
The general life cycle of the virus, as with other paramyxoviruses, begins with the 
mediation of attachment and membrane fusion with a target cell and entry into the 
cytosol.   This is a necessary and initializing step in the process of infection, occurring 
well before any replication [31].  These first steps in the process—attachment, fusion and 
entry—provide tantalizing antiviral targets with the added incentive of being able to 
impede infection before it truly begins. 
 
HMPV attachment and fusion can be performed by a single surface glycoprotein, the 
fusion (F) protein, at least in the case of clade A2 isolate CAN97-83 [23, 28].  This is a 
novel occurrence amongst paramyxoviruses, which would generally require a separate 
protein to perform each of these functions [32].  HMPV further exhibits deviation from 
the general paramyxoviral entry pathway in that, rather than entering at the cellular 
plasma membrane, the virus is likely first internalized by either endocytosis or 
macropinocytosis and gains access to the cell through fusing its lipid envelope with one 
of these membranous vesicles [25].  While this mode of entry is thought novel for 
paramyxoviruses, recent evidence suggests that hRSV also enters through such a process 
[33]. Given the diverse functions of the F protein, a greater understanding of its 
composition at the amino acid level (and interactions therein) as well as the observed 
effects from altering this sequence on activity will lend itself to explaining how this 
fusion protein performs these somewhat disparate roles. 
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While no complete structure has been solved for this protein, a combination of the 
structures of the fusion proteins from other paramyxoviruses via X-ray crystallography 
and a recently reported partial HMPV F structure demonstrate some overall homology 
among these Class I viral fusion proteins [25, 27, 34-35].  Upon performance of 
homology modeling, it became readily apparent that while there are significant 
differences between parainfluenza virus 5 (PIV5) F—the basis for the prefusion 
homology model—and HMPV F with regard to sequence identity, there is likely to be a 
degree of conservation with regard to folding, particularly the position of specific 
independently folded domains.  These conserved regions allow for classification of fusion 
proteins into one of three classes with both HMPV F and PIV5 F being grouped into 
Class I. 
 
Class I fusion proteins exist in a prefusion conformation of homotrimers that is 
metastable following a priming proteolytic event [36].  In yet another difference for 
HMPV from other paramyxoviruses, HMPV F is processed extracellularly, potentially by 
the cellular protease TMPRSS2 in vivo, rather than by an intracellular enzyme—an event 
that is recapitulated in vitro with the addition of low concentrations of trypsin [37]. This 
metastability means that all that is necessary to begin the process of fusion is a triggering 
event, which allows for the protein to begin to undergo conformational change (Figure 
1.3) [38].  Interestingly, it would appear that all energy required not only for this change 
but also for the membrane fusion event overall is contained within the macromolecule 
itself.  However, this is chiefly based on the lack of a known ATP- or GTP-dependent 
cofactor, and a contribution to the overall energetics within the system from changes to 
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lipid composition cannot be ruled out.  Following, the triggering event, which varies 
depending upon the particular protein, the hydrophobic fusion peptide, heretofore buried 
within the prefusion structure, is released and targeted toward the membrane of a 
potential host cell.  The hydrophobicity of this amino acid stretch allows it to embed 
within the acyl chains inside the lipid bilayer, effectively tethering the virus to the cell’s 
membrane (Figure 1.3B) [39].  At this point in fusion, two sets of three helices—the set 
adjacent to the fusion peptide is called heptad repeat A (HRA), while the one abutting the 
transmembrane domain on the viral envelope is called heptad repeat B (HRB)—are each 
exposed to the solvent in a new manner (Figure 1.3C) [40].  The fusion protein, now fully 
extended and tethered to two membranes, folds back onto itself much like a spring, and 
as this occurs, the two sets of heptad repeats interlock with one another to form an 
extremely stable and energetically favorable six-helix bundle (Figure 1.3D) [41].  In so 
doing, the lipids of the membranes are brought into proximity and mixing occurs.  This 
process, mediated by homotrimers of the F protein, , allows for the opening of a fusion 
pore through which the contents of the virion can enter the cell (Figure 1.3E). 
 
While the end result is the same for all Class I fusion proteins, the means of initiating the 
process can vary.  For the HMPV strain A2 isolate CAN97-83, the triggering of the 
fusion protein is pH dependent with fusion occurring at a permissive pH of 5 but not at 
neutral pH [23].  This, however, is not the case for other strains of the virus within all 
clades [24].  Such a fusion trigger is novel among paramyxoviruses but not to all viruses; 
in fact, a low-pH trigger is quite common overall.   
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The influenza virus also features a Class I fusion protein, influenza HA, and behaves in a 
similar manner and triggers at a pH of 5.4 [42].  Like HMPV F, HA is a homotrimeric 
integral membrane glycoprotein. However, the protein has more cylindrical shape, 
constituted into a central α helix coil.  It is thought that repulsive electrostatic charges 
that arise between residues following their protonation at low pH and are responsible for 
the destabilization of the prefusion form.  Such destabilization  allows the protein to 
trigger and refold into its postfusion conformation [43-44].  While electrostatic 
interactions can impact overall protein stability, the degree to which this occurs is heavily 
dependent on the location of the interacting residues as well as the surrounding 
environment.  For example, modeling studies showed a strong attraction between the 
positively charged HA1 subunits and the negatively charged HA2 subunits of influenza 
HA at neutral pH; however, at low pH, both subunits become protonated, increasing the 
repulsive force between them.  The macromolecular result is greater protein 
destabilization, which facilitates the transition to the postfusion structure [27]. 
 
Similarly, a portion of this work focuses on amino acids within the heptad repeat A 
domain as well as in a conserved region of the F2 peptide fragment of HMPV F—a 
portion of the protein that is cleaved from the rest of the polypeptide following protease 
treatment but attached by disulfide linkages—that had been shown to modulate triggering 
previously in PIV5 F [45].  It also seeks to expand upon the discovery of a putative pH-
sensing histidine residue at position 435 within the HRB-linker domain of HMPV F, 
which previous analysis of the homology model showed to be surrounded by several 
positively-charged residues, notably K295, R396 and K438.  The position of these 
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residues suggests that the electrostatic repulsion forces that arise upon protonation of 
H435 at low pH could be another driving force for fusion triggering of HMPV F [25].  
This assertion is supported by mutagenesis studies showing that alanine substitutions to 
these basic residues resulted in a dramatic decrease in fusion.  To that end, this same 
HRB-linker domain has also been demonstrated to have an important role in fusion for 
PIV5 F, so work to determine whether either region—HRA or HRB-adjacent residues—
display primacy over the other with regard to importance in triggering HMPV fusion was 
also conducted. 
 
These studies began with a ClustalW alignment of select paramyxoviral F proteins within 
the aforementioned domains (Figure 1.5).  An enrichment in charged residues at the 
HRA-F2 interface was observed for HMPV F relative to all other paramyxoviral fusion 
proteins.  Considering the role of electrostatics in influenza HA-mediated fusion and that 
HMPV F is the only member of the family to require fusion at a pH below neutral, further 
study into the role of intramolecular electrostatic interactions in HMPV F and their 
effects on triggering fusion at different pH levels were the focus.  Among the novel 
charged residues, substitution of E51, D54 and E56 resulted in drastic alterations to 
fusion activity, demonstrating their important role in the triggering and stability of the 
fusion protein.  The results of these studies elaborate on the underlying mechanism of 
HMPV F-mediated membrane fusion triggering and posit that such interactions in 
multiple regions throughout the molecule impel conformational changes. 
 
.  
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Subsection III:  HMPV Replication & Assembly 
 
In contrast to what is known about paramyxoviral fusion and entry, both generally and 
specifically regarding HMPV F function, there have been virtually no studies conducted 
on the ensuing steps in the infectious cycle, namely RNA synthesis and replication.  
There are currently very few articles in the literature that specifically addresses the RNP 
components of HMPV specifically.  The authors of that publication characterize the 
ability of the HMPV nucleocapsid protein (N) and phosphoprotein (P) to interact when 
synthesized in vitro as measured by a variety of biochemical methods [30]. Additionally, 
they report these proteins to be the minimal component for the formation of viral 
inclusion bodies.  Further, evidence from other viral systems suggests these bodies may 
be the major site of viral RNA synthesis [46-47].  Another paper discusses the ability of 
the polymerases of HMPV and avian metapneumovirus (AMPV) to complement one 
another [29].  The study found that attenuation of HMPV was observed in vivo when its 
polymerase gene was exchanged with that of AMPV while less pronounced effects had 
been observed in vitro. 
 
While these studies represent an excellent beginning to replication studies for this virus, it 
certainly is only that—a beginning.  Currently, many aspects of HMPV replication and 
processes downstream of that, including viral assembly, are based on research conducted 
on other negative strand viruses.  While this extrapolation is understandable given the 
conserved mode of action amongst these viruses and the proteins used to carry them out, 
this work describes some aspects which have not been reported explicitly for other 
negative strand viruses. 
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Upon gaining entry to the host cell, the virus utilizes its own RNA-dependent RNA 
polymerase (RdRp) to synthesize mRNA from its genomic RNA, which is encapsidated 
with a helicoidal nucleocapsid protein [48].  The RdRp is composed of the large protein 
(L) and its obligate cofactor P.  The gene encoding the L protein occupies nearly half of 
the HMPV genome, and the protein is thought to contain all enzymatic functionality for 
the RNA synthesis, including an active site, methyltransferase and guanylyltransferase.  
These area regions of enzymatic activity have been demonstrated to be well-conserved 
among Mononegavirales into discrete domains that may even fold independently of one 
another [49-50].  
 
There is some structural evidence to support L oligomerization, as electron micrograph 
results with VSV L suggest that dimerization occurs, though it is as yet unclear if this is 
relevant in the context of infection [50-52].  Work with several viruses within 
Mononegavirales suggest a mechanism by which P, as an oligomer, may deter 
aggregation of the large protein in the cytosol, allowing for proper folding and catalytic 
activity of the polypeptide in the RdRp complex [53].  In addition to this possible 
chaperone-like role, the phosphoprotein is the sole component within the viral 
complement of proteins that directly contacts both the nucleocapsid protein as well as the 
large protein, bringing the conserved Domain II of L in proximity with an encapsidated 
RNA template [54].  
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The mono- and polycistronic RNA transcripts produced by the RdRp include a 7-Me-
guanosine cap and poly-A tail, making them indistinguishable from cellular mRNA 
(Figure 1.5) [51, 55-59].  Among other observations in negative strand viruses, is an 
apparent correlation between the abundance of a viral protein during infection and its 
distance from the 3’ promoter, resulting in a gradient where the most proximal gene, N, is 
most abundant and the most distal gene, which encodes the large protein is the least.  This 
gradient has been implicated by some in the regulation of different activities of the RdRp, 
namely viral gene transcription and synthesis of antigenomic RNA. It is accepted that 
viral transcription likely precedes genomic replication [2, 60].   
 
One challenge for HMPV and similar viruses is that all RNA synthesis occurs in the 
cytosol where naked RNA would readily elicit a strong immune response through RNA 
detection proteins such as RIG-I or MDA5 [61].  Encapsidation provides some protection 
of viral RNA, but that may not be the only viral counter measure.  Much of the synthesis 
process is posited to occur within viral inclusions, which are punctate structures within 
infected cells with concentrated amounts of viral RNA and RNA-associated proteins.  In 
fact, there is some evidence for RNA to synthesis to occur in these structures at least 
initially in the case of rhabdoviruses, such as rabies and vesicular stomatitis virus (VSV)  
[46-47].  However, no such study exists for any paramyxovirus, though it has been shown 
that the minimal composition of such bodies does appear to be the N and P proteins for 
HMPV [30].    
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The presence of paramyxoviral RNP proteins and complexes thereof—namely L, P and 
N—within inclusion bodies during infection is well established [62-64]. Inclusion bodies 
have been observed readily in hRSV, and techniques such as immunofluorescence 
microscopy have even offered a glimpse of the potential organization of these bodies in 
the case of hRSV infection [65].  Within infected cells these punctate structures show the 
large protein is present exclusively at the periphery while both the phosphoprotein and—
to a greater degree—nucleocapsid proteins permeate the bodies.  By contrast, a more 
diffuse pattern is observed when antibodies specific to the hRSV matrix protein are used 
to probe the cell.  However these experiments, while informative, do not take into 
account changes over time as they were all performed at a single point post infection. 
 
Such an arrangement may not only further shield viral RNA from the innate immune 
system in the cytosol but also allow for a vast interacting face of the large protein to be 
exposed to the cytosol.  Such an arrangement would be an efficient strategy for binding 
necessary host cell factors while maintaining any polymerase activity or viral protein 
contacts.  It should be noted, however, that no study has shown the temporal-spatial 
relationship of these proteins with regard to where they localize throughout HMPV 
infection.  This aim is a focus of the research presented herein.  This work includes a 
timecourse study of HMPV-infected cells which suggests the hypothesis that inclusions 
are potential sites of RNA replication, as metabolically-labeled RNA species were 
detected in bodies at all times post-infection similar to those containing HMPV N and/or 
P.   
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For efficient infection, the virus must be able to balance polymerase activity between that 
of transcription of open reading frames and replication of the entire genome from 
antigenomic templates [66-67].  Therefore my thesis work also examined the initiation of 
these events through manipulation of the promoter properties.  The two viral promoters, 
the 3’ leader and  5’ trailer complement (as oriented in the genomic RNA), are 
canonically responsible chiefly for mediating RNA transcription and genome replication, 
respectively [68].  As viral RNA polymerization always occurs at the 3’ end of the linear 
nucleic acid template, the polymerase will bind the leader on the negative sense genomic 
RNA and either stop at gene junctions to create mRNA or read through these to 
synthesize a full-length antigenome, which will serve as a genomic template via binding 
of the polymerase at its 3’ promoter, the trailer (Figure 1.5) [2].  Additionally, the 36 
nucleotide trailer-terminal sequence (TTS) of hRSV has been shown to be indespensible 
for proper encapsidation of progeny RNA [69].  Despite quite a bit of understanding of 
hRSV and its promoter dynamics, there is no such analysis present for HMPV; as such, 
comparative studies between the two systems were performed as a part of this research to 
gain understanding on the differences between the two pathogens in this regard. 
 
This work offers data to suggest that there are signficant differences in the promoter 
efficiency between HMPV and hRSV despite large sequence conservation and similar 
predicted RNA structure.  Further, it appears that the TTS, which found is absent in 
HMPV may be responsible for some of this observed difference in viral promoter 
strength.  This work represents a first step in the process of elucidating the contribution of 
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promoter-polymerase dynamics as a factor in the large-scale ability of a virus to 
efficiently establish a productive infection in host cells. 
 
While it is crucial to understand where and when the viral RNP goes about RNA 
synthesis over the course of infection, the story is incomplete without addressing how 
these same proteins facilitate the exit of nascent virions from the infected cell.  Again, 
quite a bit can be carefully inferred about the workings and interplay of the HMPV 
nonstructural proteins from previous studies in closely related systems.  For example, 
these viral proteins often exhibit high levels of intrinsic disorder, likely to enable 
maximal plasticity with regard to interacting partners (both viral and cellular) [70].   
 
Such flexibility is displayed throughout Mononegavirales and lends itself to different 
activities being performed by the same factors throughout infection; this is made more 
complex when one also considers the importance of the temporal component of viral 
infection.  Different interactions can (and must) be made at specific points during 
infection to further the overall process [71].  This interplay of numerous interactions 
along with temporal and spatial pleiotropy throughout infections enable a relatively small 
number of viral factors to be the initiators for all steps necessary to produce a substantial 
infection in host cells, including entry, RNA synthesis, virion assembly and egress from 
cells. 
 
The potential role of inclusion bodies in the centralization of RNA synthesis has already 
been discussed; however there is also a broader question concerning these bodies and 
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their long-term fate within an infected cell.  If these sites are RNA replication centers, it 
is unclear whether and by what mechanism they incorporate into the HMPV assembly 
machinery or if there is no difference between the two and it is simply a case of 
maturation and differential protein recruitment and organization.  While characterization 
of protein-protein interactions that govern HMPV infection is key to gaining insight into 
the underlying mechanisms of HMPV infection, this goal cannot be fully attained without 
first understanding the spatial and temporal link between viral factors and activity at the 
whole-cell level.  
 
Thusly, this work also features studies seeking to shed light on the overlying HMPV 
infectious cycle at the cellular level by focusing on the interplay between HMPV N and P 
throughout the entire process.  We report that overexpression of HMPV N 
morphologically mimics early stages of HMPV infection, such as 6 hours post infection 
(hpi), with the protein seemingly aggregating.  Conversely, overexpression of HMPV P 
leads to peripheral localization and induction of filamentous extensions at the plasma 
membrane—a cellular visage more similar to a more progressive stage of infection.  
Interestingly, co-expression of HMPV N with a phosphoprotein construct that does not 
localize to inclusions leads to tight co-localization at the cellular periphery, suggesting 
that HMPV P may be modulating some of the characteristic late-stage morphology of 
HMPV infection.  Taken together, these results suggest a model in which HMPV P may 
favor activities directed toward egress while HMPV N may enhance assembly and/or 
RNA synthesis.  Productive infection requires interactions between these proteins in 
which one may exert dominance over the other at different points during infection.  
17 
 
 
 Overall, these studies examine various points throughout HMPV infection that represent 
irreversible checkpoints.  Whether it be the triggering of membrane fusion under 
permissive conditions, the ramping up of viral RNA synthesis and the underlying 
processes that mediate this event or the conglomeration of the HMPV nonstructural 
proteins at later stages of infection, the overarching theme is an analysis of the 
orchestrated steps by which an HMPV particle first encounters a host cell through the 
time at which progeny virus egress.  
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Figure 1.1. Phylogenetic tree lineage analysis of negative-sense RNA viruses. 
The phylogenetic tree diagram illustrates the diversity of select members of the order 
Mononegavirales based upon primary protein sequence similarity of the phosphoprotein.  
Longer branches indicate greater phylogenetic distance between viruses.  Subfamilies 
within Paramyxoviridae highlighted in red while distinct viral families are denoted in 
black.  HMPV falls into its own subfamily with hRSV within the paramyxoviral family.  
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Figure 1.2. Architecture of a generalized Paramyxovirus infectious particle. 
Paramyxoviruses produce pleiomorphic virions that contain a ribonucleoprotein core, 
also known as the nucleocapsid.  It contains all necessary components necessary for viral 
RNA synthesis, including the negative-sense RNA gene as well as the N, P and L 
proteins.  The viral envelope is the outer leaflet of the particle’s host-derived lipid bilayer 
and contains the spike glycoproteins F and G about its surface while the matrix protein is 
closely associated with the inner leaflet of the bilayer, maintaining the virion’s shape.  
Image reused with permission from journal (modified from Smith EC, et al. FEBS J. 
276(24):7217-27, 2009).  
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Figure 1.3. Schematic of the Class I viral fusion mechanism. 
This cartoon depicts the Class I viral fusion protein mode of action.  (A) The metastable 
prefusion form is triggering, (B) releasing the fusion peptide, (C) which then inserts into 
the target membrane.  (D) The protein undergoes a large-scale conformational 
rearrangement such that the two sets of exposed heptad repeats coalesce to form a (E) 
six-helix bundle, resulting in the irreversible postfusion conformation.  The consequence 
of the proteins actions is lipid mixing between the outer leaflets of the two bilayers and 
fusion pore formation.  Image reused with permission from journal (modified from 
Chang A, et al. Viruses 4(4):613-36).  
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Figure 1.4. HMPV F models well onto the PIV5 F crystal structure. 
HMPV CAN97-83 fusion protein was threaded through the PIV5 F crystal structure 
(MMDBID: 37132).  The modeling exhibited high similarity to the original structure with 
no secondary structural anomalies, such as prolines or glycines modeled within alpha 
helices.  Further, the disulfide linkage that is common among all paramyxoviral F 
proteins is properly oriented with the cysteine residues in register to form such a bond.  
The inset of the homology model (left) illustrates the predicted orientation of H435 
(yellow) about several adjacent positively-charged moieties (red).  The region is also 
circle within the PIV5 crystal structure (right). 
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Figure 1.5. HMPV F is enriched with charged amino acids in the F2-HRA region. 
(A)  Illustration of approximate location of areas of interest within HMPV F using the 
PIV5 F crystal structure.  (B) Comparison of HMPV F CAN97-83 and PIV 5 F homology 
within HRA-F2 region.  Select charged residues are labeled in each rendering. (C) 
HMPV F (amino acids 47-57 [top] and 161-168 shown) was aligned to other viral fusion 
proteins using the ClustalW alignment tool.  The conserved block F2 (CBF2) region 
possesses a much greater amount of charged amino acids relative to the other viral fusion 
proteins. There were also novel charged amino acids observed in the heptad repeat A 
(HRA) region of HMPV, the adjacent area to CBF2 in prefusion models of the protein.  
The circled residues were selected for further study and site-directed mutagenesis.  
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Figure 1.6. Paramyxoviral RNA synthesis requires two promoters. 
Nucleocapsids are shown as arrays of triangles, each binding six nucleotides of viral 
RNA, with white lines denoting gene junctions.  During transcription, the polymerase 
reads from the 3’ end after initiating synthesis at the leader promoter region.  It 
synthesizes capped, poly-adenylated mRNA transcripts made by stopping and restarting 
at each junction.  These are read through during replication, yielding antigenomic RNA, 
which serves as a template for more RNA genomes by synthesis initiated at the trailer 
promoter region. 
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Chapter II:  Methods and Materials 
 
Subsection I:  HMPV Fusion Project 
 
Cell Lines.  Vero and BSR cells (provided by Karl-Klaus Conzelmann, Max Pettenkofer 
Institut) were grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco Invitrogen, 
Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and 
streptomycin (P/S).  The media of BSR cells was supplemented with 0.5mg/mL G418 
sulfate (Gibco Invitrogen, Carlsbad, CA) every third passage to select for T7 polymerase 
expression. 
 
Plasmids and Antibodies. The HMPV F gene within the pGEM‐3Zf(+) vector was 
provided by Ursula J. Buchholz (NIAID, Bethesda, Maryland) with permission from Guy 
Boivin (Centre Hospitalier Universitaire de Québec, Quebec City, Quebec, Canada). The 
HMPV F H435R, H435K, H435D, H435E, E51A, D54A, E56A, R163A, R166A, E51K, 
E51K/H435R, D54A/E56A, D54A/E56A/H435R, D54A/H435R, E56A/H435R, 
D54N/E56Q, and D54N/E56Q/H435R protein mutants were created using QuikChange 
site‐directed mutagenesis according to manufacturer’s protocol (Stratagene). The HMPV 
F wild type (WT) and mutant genes were released from pGEM‐3Zf(+) and ligated into 
the pCAGGS mammalian expression vector and sequenced in their entirety after ligation. 
Antipeptide antibodies against HMPV F (Genemed Synthesis, San Francisco, CA) were 
generated using amino acids 524‐538 of HMPV F. 
25 
 
 
Viruses. Recombinant, GFP‐expressing HMPV (rgHMPV) strain CAN97‐83, a genotype 
group A2 virus with a codon stabilized SH gene (2) was kindly provided by Peter L. 
Collins and Ursula J. Buchholz (NIAID, Bethesda, Maryland). HMPV, at a starting MOI 
of 0.01, was propagated in Vero cells incubated at 32°C with Opti‐MEM supplemented 
with 200mM L‐glutamine and replenished with 0.3μg/mL TPCK‐trypsin every day. On 
the seventh day, cells and media were collected and frozen at ‐80°C. The virus-containing 
solution was thawed to 37°C and subjected to centrifugation at 2500 rpm for 10 min at 
4°C on a Sorval RT7 tabletop centrifuge.  The supernatant was then subjected to a 
centrifugation over a 20% sucrose cushion for 2 hours and fifteen minutes at 27,000 rpm 
4°C using a SW28 swinging bucket rotor on a Beckman Optima L90‐K Ultracentrifuge. 
The resulting pellet was resuspended in 500μL of Opti‐MEM, left at 4°C overnight, 
divided into aliquots the next morning and stored at ‐80°C. Viral titers were performed by 
on a 96‐well plate and counting the number of GFP-expressing cells the following day.  
 
Syncytia Assay in Transfected Cells. Subconfluent monolayers of Vero cells plated in 
6‐well plates were transiently transfected with a total of 0.5μg of DNA consisting of 
pCAGGS‐HMPV F WT, pCAGGS‐HMPV F protein mutants, or the empty pCAGGS 
vector (MCS control) using Lipofectamine and Plus reagents (Invitrogen) according to 
the manufacturer’s instructions. The next morning, confluent cell monolayers were 
incubated at 37°C in 1mL Opti‐MEM with 0.3μg/mL TPCK‐trypsin for 1.5 hours. Cells 
were then subjected to four 4-minute pH pulses every 2 hours with 1 mL of PBS of the 
indicated pH buffered with 10mM HEPES and 10mM MES at 37°C.  After an overnight 
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incubation at 32°C in order to allow final cellular rearrangements to take place, digital 
photographs of syncytia were taken with a Spot Insight Firewire digital camera mounted 
on a Carl‐Zeiss Axiovert 100 inverted microscope using a 10x objective (Thornwood, 
NY). 
 
Reporter Gene Fusion Assay. Vero cells in sixty‐millimeter dishes were transfected 
with 0.55μg pCAGGS‐HMPV F wild type (WT) or mutant F protein and 0.55μg T7 
control plasmid (Promega, Madison, WI) containing luciferase cDNA under control of 
the T7 promoter using Lipofectamine and Plus reagents according to the manufacturer’s 
instructions. The following day, Vero cells in one sixty-millimeter dish were lifted from 
the plate surface and subjected to centrifugation at 1300 rpm, 4°C in a Sorval RT7 
tabletop centrifuge for 5mins.  Cells were resuspended in 2 mL of DMEM plus 10% FBS 
and 1% P/S and overlaid onto two 35‐millimeter dishes of confluent BSR cells (1mL of 
Vero cells per 35‐millimeter dish). Cells were incubated at 32°C for 1.5 hours and then 
treated with 1mL of PBS of the indicated pH buffered with 10mM HEPES and 10mM 
MES for 4 minutes at 37°C. Buffered PBS was replaced by 1mL of Opti‐MEM with 
0.3μg/mL TPCK‐trypsin and the pH pulse was repeated one hour after. Cells were then 
incubated in 2mL DMEM with 10% FBS and 1% P/S at 37°C for 4 hours to allow for 
luciferase production. Luciferase activity was assessed using a luciferase assay system 
(Promega) according to manufacturer’s protocol. Light emission was measured using an 
Lmax luminometer (Molecular Devices, Sunnyvale, CA) for 5 seconds with a 1.6 second 
delay between each measurement. 
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Protein Expression, Metabolic Labeling, Surface Biotinylation, and 
Immunoprecipitation. Cells in sixty-millimeter dishes were transfected with 1.10μg 
pCAGGS‐HMPV F wild type (WT) or mutant F proteins  (empty pCAGGS as control 
MCS) using Lipofectamine and Plus reagents according to manufacturer’s’ protocol. At 
18‐24 h post‐transfection, cells were starved in methionine‐ and cysteine-deficient 
DMEM for 1 hour and then metabolically labeled with Tran[
35
S] label (100μCi/mL; 
Perkin‐Elmer) with 0.3μg/mL TPCK‐trypsin for 4 hours. Following radiolabeling, cells 
were washed three times with ice‐cold pH 8 PBS and surface proteins were biotinylated 
with 1mg/mL EZ‐Link Sulfo‐NHS‐Biotin (Pierce, Rockford, IL) diluted in pH 8 PBS for 
30 minutes, rocking at 4°C and then for 20 min at room temperature. Cells were lysed in 
1mL RIPA buffer containing 1 KalliKrein inhibitory unit of aprotinin (Calbiochem, San 
Diego, CA), 1mM phenylmethylsulfonyl fluoride (Sigma, Saint Louis, MO) and 25mM 
iodoacetamide (Sigma) after removal of the biotin solution. The lysates were subjected to 
centrifugation at 136,500 × g for 15 min at 4°C, and supernatants were collected. 
Antipeptide sera and protein A-conjugated sepharose beads (Amersham, Piscataway, NJ) 
were used to immunoprecipitate the F proteins as previously described (27). 
Immunoprecipitated protein was boiled away from the beads using a total of 100μL of 
10% SDS (40μL for first boil and 60μL for second boil). Fifteen percent of total protein 
collected was used for total expression analysis and the remaining 85% was diluted in 
500μL biotinylation dilution buffer (20mM Tris [pH 8], 150mM NaCl, 5mM EDTA, 1% 
Triton X‐100, 0.2% bovine serum albumin) and incubated with immobilized streptavidin 
(Thermo Scientific, Rockford, IL) for 1 hour at 4°C. Samples were washed, resolved by 
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SDS‐15% polyacrylamide gel electrophoresis (SDS‐PAGE), and visualized using the 
Typhoon imaging system. 
 
Homology modeling. A model of the prefusion conformation of the HMPV F protein 
was generated via a threading methodology from the molecular coordinates (mmdbld: 
37132) determined from the crystal structure of the prefusion form of PIV5 F [35].   
Modeling was performed with DeepView/Swiss-PdbViewer v4.0.1 
(www.expasy.org/spdbv) as previously described [72].  This method yielded a protein 
that maintained all predicted secondary structure (e.g. no glycine or proline in alpha 
helices) and disulfide linkages (Figure 1.4). 
 
  
29 
 
Subsection II:  HMPV Minireplicon Project 
 
Plasmid vectors.  The HMPV P and M2-1genes were synthesized by RT-PCR from 
HMPV strain CAN97-83 and cloned into the pCAGGS expression vector using EcoRI 
and either XhoI or ClaI, respectively. Codon-optimized HMPV N and L genes (provided 
by Dr. Ursula J. Buchholz, NIAID, Bethesda MD) were also expressed in pCAGGS. The 
RSV luciferase minigenome plasmid was a generous gift from Dr. Richard Plemper 
(Emory University, Atlanta, GA) in addition to the RSV N, P, L and M2-1 vectors.  PIV5 
N, P and L plasmids were provided by Dr. Anthony Schmitt (Pennsylvania State 
University, University Park, PA).  PCR extension was implemented in order to obtain the 
HMPV P-FLAG construct from the wildtype construct within a pGEM2X vector.  This 
method was also employed to add the RSV trailer-terminal sequences to the HMPV 
minireplicon plasmids. 
 
Viruses.  Recombinant, GFP-expressing forms of different viruses were provided by the 
following:   hRSV by Mark Peeples (Ohio State University), parainfluenza virus 5 (PIV5) 
by Robert Lamb (Howard Hughes Medical Institute, Northwestern University) and 
vesicular stomatitis virus (VSV) by Michael A. Whitt (University of Tennessee Health 
Science Center, Memphis, Tennessee).  
 
Minireplicon assay. BSR cells were grown overnight in 24-well plates and then co-
transfected with a specific minireplicon plasmid along with other various combinations of 
DNA constructs (total of 2.5µg) with Lipofectamine LTX and Plus reagents according to 
manufacturer’s protocol.  After overnight incubation, cells were washed twice with PBS 
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and dispensed 1mL/well DMEM with FBS and antibiotic was added.  Cells were then 
incubated at 37°C for 1h prior to infection at an MOI of 5 with specific virus stock or 
SPG buffer (mock infection).  Again cells were incubated overnight with virus stock at 
37°C.  24 or 36 hours post infection, cells were washed twice with PBS and lysed in 
0.1mL Promega 1X reporter gene lysis buffer.  Plates were then briefly stored at -20°C 
before being thawed.  Lysates were transferred to centrifuge tubes on ice and spun at 
13,000rpm for 1 min at 4°C.  25µL of the supernatant was then transferred to an opaque 
luminometer plate.  Luciferase activity was assessed using a luciferase assay system 
(Promega) according to manufacturer’s protocol. Light emission was measured using an 
Lmax luminometer (Molecular Devices, Sunnyvale, CA) for 30 seconds with a 1 second 
delay between each measurement. 
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Subsection III: HMPV Assembly Project 
 
Cell Lines. A549 cells (provided by Hsin-Hsiung Tai, University of Kentucky) were 
grown in RPMI medium supplemented with 10% FBS and 1% P/S.  
 
Antibodies. HMPV P rabbit antiserum was kindly provided by Dr. John V. Williams 
(Vanderbilt University, Nashville TN). Monoclonal antibodies against HMPV P (NBP-
21631, Novus Biologicals, Littleton, CO) and HMPV N (ab94802, Abcam, Cambridge, 
MA) were purchased commercially. 
 
Protein Expression, Metabolic Labeling, and Immunoprecipitation. A549 cells in 
thirty-five millimeter dishes were transfected with 2.75μg HMPV N, P or L constructs in 
pCAGGS (empty vector as control [MCS]) using Lipofectamine LTX and Plus reagents 
according to manufacturer’s protocol. At 18-24 h post-transfection, cells were infected or 
mock infected for 24h. Cells were then starved of methionine and cysteine in DMEM 
lacking these amino acids for 30min and metabolically labeled with Trans[35S] label 
(100μCi/mL; Perkin-Elmer) for 4 hrs. Following radiolabeling, cells were washed three 
times with ice-cold pH 7.2 PBS before being lysed in 0.5mL lysis buffer (20mM Tris-
HCl pH 7.5, 150mM NaCl, 1mM Na2EDTA, 1mM EGTA, 1% Triton-X 100, 2.5mM 
sodium pyrophosphate, 1mM beta- glycerophosphate, 1mM sodium orthovanadate, 
1μg/ml leupeptin). The lysates were subjected to centrifugation at 136,500 × g for 15 min 
at 4°C, and supernatants were collected. Antipeptide sera or monoclonal antibodies and 
protein A-conjugated sepharose beads (Amersham, Piscataway, NJ) were used to 
immunoprecipitate the proteins of interest as previously described above. Samples were 
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washed, resolved by SDS-15% polyacrylamide gel electrophoresis (SDS-PAGE), and 
visualized using the Typhoon imaging system. 
 
Western Blotting. Following transfection or infection as previously described, A549 
cells in thirty five millimeter dishes were lysed in 0.5mL RIPA buffer containing and 1X 
concentration of Complete Mini protease inhibitor cocktail (Roche, Indianapolis, IN). 
Lysates were then homogenized and centrifuged at 13,000rpm for 25min at 4°C. The 
supernatants were then collected and either treated with antibodies and protein-A 
sepharose beads as described above or fractions of whole lysates were resolved by 15% 
SDS-PAGE. Proteins were then transferred to PVDF membranes (Millipore, Billerica, 
MA) with a BioRad Trans-Blot SD semi-dry transfer cell and transfer buffer (48mM tris, 
38.9mM glycine in 20% methanol). Antibody dilutions were conducted in 5% milk tTBS 
with primary incubation overnight and secondary for 1h, both at 4°C.  Proteins were 
visualized using the Odyssey infrared imaging system (LI-COR, Lincoln, NE). 
 
Immunofluorescent detection of proteins. Following treatments, A549 cells on glass 
coverslips within thirty five millimeter dishes were washed three times with pH 7.2 
PBS+0.02% NaN3 (PBSN) before being fixed with 4% formaldehyde for 15 minutes at 
RT. Cells were washed twice more in PBSN then permeabalized with 1% Triton X-100 at 
4°C for 15 minutes.  Coverslips were then blocked in PBSN containing 1% FBS for at 
least 1h before administration of primary antibodies in the same buffer overnight at 4°C. 
Secondary antibodies were applied in the dark at 4°C for 1h before mounting coverslips 
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to glass slides with Vectashield mounting medium (Vector Laboratories, Burlingame, 
CA). 
Confocal microscopy. Immunofluorescence images were acquired from the Nikon 
A1confocal microscope and processed using NIS Elements software (Nikon Instruments, 
Melville, NY). 
 
Measurement of viral particle release from infected cells. A549 cells were infected 
with HMPV viral stock (MOI=5) in sixty millimeter dishes as previously described for 
variable lengths of time with the medium being changed at 4h post infection. At the end 
of the infection period, the whole supernatant was collected and stored at -80°C 
overnight. The medium was thawed to 37°C, centrifuged at 2500rpm for 10min at 4°C on 
a Sorval RT7 tabletop centrifuge with the supernatant then subjected to centrifugation 
over a 20% sucrose cushion for 2.5h at 27,700rpm 4°C using a SW41 swinging bucket 
rotor on a Beckman Optima L90-K Ultracentrifuge. The resulting pellet was resuspended 
in 30μL OptiMEM and boiled for 10min prior to being resolved with 15% SDS-PAGE. 
Western blotting was conducted as previously described. 
 
BrUTP incorporation into cellular RNA and detection. The protocol for this 
experiment was adapted from one previously described for VSV [20]. Briefly, BSR cells 
on glass coverslips within thirty five millimeter dishes were infected with WT HMPV 
stock (MOI=5) for variable lengths of time. Five hours prior to the end of the infection 
period, cells were washed with PBS and dispensed glucose-free DMEM supplemented 
with 1mM glucose and 20mM GlcNac for a period of 2h. A portion of the same media 
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was then pre-incubated at RT with 10mM 5-bromouridine 5′-triphosphate sodium salt 
(Sigma) and Lipofectamine 2000 for 30min prior to being added to the cells for 3h. Cells 
were then fixed with 2% paraformaldehyde for 15min at RT, treated with ice cold 
methanol for 3min and then permeabalized in PBS containing 1% bovine serum albumin 
(PBSA) and 0.1% Triton X-100 for 10min at RT. Cells were blocked overnight in PBSA 
then treated with anti-BrdU mouse monoclonal antibody conjugated to AlexaFluor488 
(Invitrogen) diluted 1:50 overnight in PBSA+0.05% Triton X-100 (PBSAT). GAM-FITC 
(Jackson ImmunoResearch Laboratories, West Grove, PA) was added at 1:300 in PBSAT 
for 1h before mounting coverslips to glass slides. 
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Figure 2.1. HMPV reporter gene fusion assay protocol. 
The reporter gene fusion assay is similar to the syncytia assay in that a plasmid encoding 
HMPV F is transfected into Vero cells to gauge fusogenicity.  However, in addition to 
HMPV F, a T7 luciferase construct is co-transfected.  Luciferase is an enzyme whose 
expression can be quantified by the measurement of the product of the chemiluminescent 
reaction it catalyzes.  In this case, the enzyme can only be expressed in the presence of 
the T7 polymerase, which is lacking in Vero cells.  24 hours post-transfection, the Veros 
are lifted and overlayed onto BSR cells, which constitutively express T7 polymerase.  
After allowing for attachment of the cells, 2 minute pH pulses are perfomed.  Ultimately, 
active fusion proteins will be able fuse the membranes of the Vero and BSR cells, 
allowing for expression of luciferase.  At that point, a luminometer can quantify 
luciferase expression as a readout on fusion activity.  
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Figure 2.2. HMPV F surface biotinylation assay protocol. 
Surface biotinylation is performed to quantify total F protein expression level as well as 
the population that persists on the cell surface.  It entails transfecting cells with HMPV F 
followed by metabolic radiolabeling with 
35
S to allow for visualization.  Next the cells 
are biotinylated, which will mark the surface expressed protein only.  Afterward, the cells 
are lysed and antibody to HMPV F applied.  All bound protein is pulled down with 
Protein A followed by treatment with 10% SDS.  At this point, a portion of each sample 
is kept retained to represent the total protein.  The rest is then treated with streptavidin 
beads, which can then be pulled down.  This portion of the sample is kept to represent the 
surface population of the protein.  Each set of samples can then be resolved via SDS-
PAGE.  
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Figure 2.3. Schematic of HMPV minireplicon assay. 
Plasmid constructs all feature leader and trailer sequences specific to HMPV or RSV 
flanking the luciferase open reading frame.  Plasmids are either co-transfected into BSR 
cells with plasmids encoding viral replication proteins (N, P and L) or transfected alone.  
If transfected alone, cells are infected with live virus at 24hours post transfection to allow 
T7 polymerase to create minireplicon RNA prior to infection.  At 24 hours post infection  
(or transfection if no infection), cells are lysed and luciferase levels measured using its 
ability to catalyze a chemiluminescent reaction.  
  
38 
 
Chapter III:  Experimental Results 
 
Subsection I:  HMPV Fusion Project 
 
An electrostatic-rich region in F2 modulates HMPV F low pH-dependent fusion 
Previous work in the lab had established that the activity of the fusion protein of the 
HMPV strain CAN97-83 (Clade A2)  is pH-dependent [23, 25].  One region that has been 
demonstrated to be critical for pH sensing is centered around H435.  This residue is in 
proximity to basic amino acid side chains (K295, R396, and K438) in the homology 
modeling based on the crystal structure of PIV5 F.  The working model for H435 as a pH 
sensor is that upon exposure to low pH, the residue is protonated and that this event 
results in an electrostatic repulsion.  Subsequently, the protein is able to trigger fusion.  
This model is supported by mutagenesis studies that showed that substitution with an 
acidic side chain (H435D, H435E) yielded a protein incapable of fusion while H435R 
exhibited a hyperfusogenic phenotype [27]. 
 
Further analysis of the HMPV F homology model indicated that a region of the protein 
that had been shown to be crucial to triggering in PIV5 F, CBF2-HRA, was enriched in 
charged amino acids in HMPV F [73-74].  The CBF2 amino acids of interest included 
E51, D54 and E56 (Figure 1.5).  These were in proximity within the model to HRA 
residues R163 and K166 (Figure 1.5).  These findings led to the hypothesis that charge-
charge interactions in this region could potentially contribute to the low pH triggering of 
HMPV F.  Measurements from our homology model estimated the distance between β-
carbons of these residues to be between 4 and 11Å, a distance permissible for the 
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formation of salt bridges between side chains at neutral pH, potentially stabilizing the 
overall structure of HMPV F (Table 3.1) [27].  It is known that charged groups of the side 
chains need to be less than 4Å apart for salt bridge formation [75-76].  While the 
modeling places some of these distances slightly outside this parameter, it is possible that 
such a highly charged microenvironment could facilitate alteration to side chain pKa.  
This would allow protonation upon exposure to a pH 5 environment and make up the 
distance between potentially bridged moieties.  Such a change to the protonation state of 
E51, D54 and/or E56 may also result in destabilization and triggering of fusion.   To 
determine what role, if any, these residues, play in low pH-dependent fusion activity, the 
HMPV F mutants E51A, D54A and E56A (F2 mutants) as well as R163A and K166A 
(HRA mutants) were created and tested for proper expression and fusogenic activity at 
various pH. 
 
With the exception of the E51A mutant, for which surface F1 expression was 66% of WT, 
all F2 and HRA mutants were expressed close to or above WT levels on the surface of 
transfected Vero cells (Figure 3.1A and 3.1B).  After determining the expression level for 
each mutant, fusogenicity was determined for each mutant protein via syncytia and 
reporter gene fusion assays.  In the former, the protein is transfected into Vero cells, 
which are subsequently treated with various buffers in the pH range of 5-7.  The ability of 
the protein to facilitate fusion is qualitatively measured by the number of multi-nucleated 
cells observed at four such pH pulses.  For the reporter gene assay, the Vero cells are co-
transfected with F and a luciferase gene with a T7 promoter.  These are overlaid with 
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BSR cells containing a T7 polymerase.  Fusion between the cell types is then measured 
by the amount of luciferase produced and quantified by biochemiluminescence. 
 
All mutants were able to promote efficient syncytia formation at pH 5 except HMPV F 
E51A (Figure 3.2B).  Cells expressing the HMPV F D54A, E56A, R163A and K166A 
mutants produced more numerous and larger size syncytia compared to WT at pH 5.  
Conversely no syncytia formation was observed in cells transfected with HMPV F E51A 
despite a significant presence of protein on the cell surface (Figures 3.1 and 3.2).  
Surprisingly, all mutants save HMPV F E51A also demonstrated syncytia at pH 6, albeit 
smaller (Figure 3.2A).  Syncytia formation was significantly lower at pH 6 relative to pH 
5 and was undetectable at pH 7. 
 
In agreement with the syncytia assay, all the mutant HMPV F proteins with the exception 
of E51A were able to efficiently promote fusion at pH 5 in the reporter gene assay 
(Figure 3.2B).  In fact, the D54A, E56A and K166A mutants promoted fusion by at least 
25% above WT.  The HMPV F R163A mutant exhibited similar fusion activity to WT 
while fusion activity for HMPV F E51A was at near background levels.  The HMPV F 
D54A, E56A and K166A mutants all promoted fusion above WT levels at pH 5.5 as well 
though, as seen with WT, the fusogenic activity was reduced by more than 50% relative 
to pH 5.  Fusion levels for HMPV F R163A were similar to WT, but no fusion above 
background was observed for HMPV F E51A at pH 5.5.  Interestingly, treatment with pH 
6 buffers drove no fusion activity above background for any of the mutants.   
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This result likely highlights the difference between the syncytia and the reporter gene 
assays in terms of how each measures the kinetics of fusion as well as by different 
amounts of activate F present at the surface.  While luciferase production was assessed 
after two pulses spaced one hour apart, syncytia formation was induced by a total of four 
pH pulses given every two hours.  Further, for the luciferase reporter to be synthesized, a 
pore large enough to transfer plasmid DNA or the T7 polymerase must be formed 
between the time of the pH pulse and cell lysis (4 hours).  In contrast, syncytia formation 
is measured after an overnight incubation, which allows sufficient time for slower 
proteins to undergo the conformational changes needed to enlarge the fusion pore [77]. 
 
E51 is required for the proper local folding and cleavage activation of HMPV F 
The results for the F2 and HRA mutants suggest that this region plays two important yet 
different roles in the stability and triggering of HMPVF. E51 appears to be involved in 
the overall fusion activity of HMPV F and could potentially serve as another pH sensor. 
Therefore, to test whether E51 acts similarly to H435, expression and fusion of the 
HMPV F E51K mutant were assessed. 
 
Substitution of E51 with a lysine (E51K) decreased the surface expression levels of the F1 
form of HMPV F by nearly 50% (Figure 3.4A and B).  While we did not test this directly, 
the observed reduction in surface expression observed for both the E51A and E51K 
mutants suggests that the negative charge at this position is important for stability of the 
protein at the cell surface.  The importance of this residue is underscored by the fact that 
the portion of the HMPV F E51K mutant that remained on the surface also failed to 
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promote cell-to-cell membrane fusion at any pH, as assessed by our reporter gene and 
syncytia assays. 
 
To test whether there is crosstalk between E51 and H435, the mutation E51K/H435R was 
also made and analyzed.  Like HMPV F E51K, surface expression of E51K/H435R was 
reduced.  Furthermore, cell-to-cell fusion activity was not detected at any pH despite the 
introduction of the hyperfusogenic mutation H435R (Figure 3.5).  These results suggest 
that the E51K mutation is dominant over H435R and confirms that residue E51 plays a 
key role in the overall function of F. 
 
Although the HMPV F E51A, E51K AND E51K/H435R mutants showed a lower surface 
expression, a significant amount of the mutant F reached the cell surface, suggesting that 
the effect of these mutations on the overall structure is not severe enough to result in 
complete ER retention due to gross misfolding.  Since E51 is near the cleavage site of 
HMPV F, electrostatic interactions involving this moiety may be important for the proper 
folding and positioning of the proteolytic processing site.  To test this, surface expression 
of HMPV F E51A and E51K was examined in the absence of trypsin.  Though HMPV F 
strains or mutants have been identified in which some processing to the mature F1+F2 is 
observed in the absence of exogenous trypsin [78-79], WT HMPV CAN97-83 F protein 
cleavage in vitro has been shown in our laboratory and others to require trypsin treatment 
[80-82].  Fitting with this, WT HMPV F protein was observed in the mature, cleaved F1 
form only after addition of trypsin whereas more than 30% of the E51A and E51K 
mutants were observed to cleaved in the absence of trypsin (Figure 3.3).  This result 
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suggests that the removal of the negative charge at position 51 caused local misfolding 
that exposed a cleavage site normally not accessible to an endogenous protease.  
Consequently, this aberrant cleavage event did not result in a fusogenically active F 
protein whenever this amino acid was substituted.  These results therefore suggest that 
E51 is important for positioning of the fusion peptide for proper proteolytic processing. 
 
D54 and E56 in F2 are important for HMPV F prefusion and postfusion stability 
The hyperfusogenic phenotype observed for HMPV F D54A and E56A suggests that 
these residues are involved in modulating the stability of the protein, potentially through 
salt bridge interactions with R163 and K166 in the prefusion state.  At low pH, 
neutralization of D54 and/or E56 may disrupt these salt bridges, allowing F to trigger.  
HMPV F double mutants D54A/E56A and D54N/E56Q were created and analyzed to 
determine the effects of disrupting these potential interactions.  The latter mutation, 
D54N/E56Q, is a more conservative, isosteric substitution that removes the charged 
residues while maintaining polarity at these residues.  Analysis of the R163 and K166 
mutations was not pursued further due to the location of these residues in HRA, as their 
potential role in six-helix bundle formation means fusion changes may not be directly 
attributed to triggering.  Additionally, HMPV F D54A/H435R, E56A/H435R, 
D54A/E56A/H435R and D54N/E56Q/H435R mutants were made to test whether 
changes in one region influence the other. 
 
While the HMPV F D54A or E56A mutants expressed at or above WT levels (Figure 
3.1A), surface expression of the F1 form of the double alanine mutant (D54A/E56A) 
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decreased by more than 40% (Figure 3.4).  Consistent with a decrease in surface 
expression levels, a reduction in fusion activity was also observed for the HMPV F 
D54A/E56A mutant.  The more conservative polar substitutions (D54N/E56Q), in 
contrast, restored the surface expression to WT levels (Figure 3.4), suggesting that either 
polar residues or steric similarity is needed to stabilize the prefusion form of the protein. 
 
According to our reporter gene fusion assay, fusion activity was significantly enhanced 
for HMPV F D54N/E56Q at pH 5 (Figure 3.5A) to levels equivalent to E56A.  However, 
the effect of these mutations on the stability and fusogenic activity of the protein is 
different.  D54N/E56Q is more hyperfusogenic at pH 5.5 compared to E56A and, while 
the addition of the H435R mutation to D54N/E56Q (D54N/E56Q/H435R) had a modest 
effect on fusion at pH 5.5, E56A/H435R exhibited a dramatic increase in fusion activity 
at the same pH.  More importantly, analysis of the syncytia assay revealed that  cells 
expressing the HMPV F D54N/E56Q and D54N/E56Q/H435R mutants produced 
numerous syncytia but significantly smaller in size compared to WT, E56A and 
E56A/H435R when triggered at pH 5 (Figure 3.5B).  The greater amount of smaller 
syncytia agree with the hyperfusogenic phenotype observed in the reporter gene fusion 
assay as this would result more cells fusing and increased luciferase production.  Thus, 
our data indicate that the replacement of the negative charges at positions 54 and 56 alter 
the stability of the fusion protein as evidenced by changes in surface expression and 
fusogenic activity. 
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The addition of the hyperfusogenic mutation H435R (D54A/H435R, E56A/H435R, 
D54A/E56A/H435R and D54N/E56Q/H435R) did not significantly alter the fusion levels 
of the mutant proteins at pH 5 (Figure 3.5).  However, the presence of the H435R 
mutation led to a modest increase in fusion activity at pH 5.5 with the notable exceptions 
of D54A/H435R and E65A/H435R, where the increase in fusion was significantly more 
pronounced.  Together with a minor decrease in F1 surface expression (Figure 3.4), our 
data suggest that H435R also affects the stability of the protein, allowing it to trigger at a 
higher pH.  This destabilizing addition of a basic residue to an already positively charged 
region can indeed be responsible for the hyperfusogenic phenotype of H435R, as 
disruptions of charge-charge interactions has been shown to alter the triggering threshold 
of influenza HA [83-84].  The pH dependency of HMPV F-mediated membrane fusion, 
however, was not abolished by mutations at positions 54 and/or 56.  Therefore, while 
H435 mediates the stability of the HRB-linker region to behave as a pH sensor, the 
stability effect conferred by residues D54 and E56 is not involved in sensing low pH. 
 
Summary 
The work on this project has illustrated the complexities in the process of triggering the 
HMPV fusion protein.  While we originally hypothesized that electrostatic interactions at 
both H435 and in the CBF2 region change in response to a lower pH environment, thus 
triggering the conformational changes needed for fusion, the fact that mutations in these 
regions could not overcome the requirement for low pH suggests that at least one other 
area of the protein may be playing a role.  Further, the combination of hyperfusogenic 
mutations, such as H435R with D54A and E56A seemed to only destabilize the prefusion 
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form while isosteric substitutions for the latter two demonstrated that more than 
electrostatic interactions are likely responsible for maintenance of metastability.  Finally, 
the mutagenesis at E51 showed that this region that has a role in triggering may also be in 
control of other processes, such proteolytic processing, adding yet another layer of 
complexity. 
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Subsection II:  HMPV Minireplicon Project 
 
While my initial work focused on the regulation of the HMPV F protein and viral entry, 
far less is known about the processes governing transcription for HMPV.  As such, the 
next studies focused on what occurs after entry, namely RNA synthesis, through the use 
of a minireplicon system.  This plasmid-based assay allows for study of viral promoter 
activity as measured through the transcription of a reporter gene, which was luciferase in 
this case.  My hypothesis was that HMPV and hRSV promoter sequences would be able 
to equally drive gene expression given HMPV- or hRSV-specific RNA synthesis 
proteins.  The basis for this position is the fairly high identity (45.5% ,100% through the 
first 11nt) for the leaders  and trailers (83%, 100% through the first 12nt).  
 
Drastic differences observed in the predicted RNA structure of various NNS viral 
promoters. 
Prior to initiating experimental examination of the HMPV promoter region, the predicted 
RNA fold of each of the native viral promoters was assessed using SplicePort software.  
Because of the several reported studies on the activities of hRSV promoters and that 
pathogen’s similarity to HMPV in other aspects, both the leader and trailer folding 
predictions of these two members of the Pneumovirinae subfamily were compared.   
 
 
There was an overall similarity of fold between the trailer promoters, despite the hRSV 
trailer being significantly longer, with both featuring a large loop with two stem loops—
one minor and one major (Figure 3.6A).  The principal differences were the angle 
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between the two stem loops (roughly perpendicular for hRSV and approx. 135° for 
HMPV) and the terminal addition to the RSV promoter.  This addition appeared to be a 
self-folding portion of the trailer directly abutting the portion with predicted structural 
homology to HMPV.  Given these structural predictions, it seemed plausible that the 
polymerase of one virus could recognize and drive transcription from the promoter of the 
other. 
 
Consequently, the predicted folds of the HMPV and hRSV leader promoters were largely 
similar (Figure 3.6B).  In both cases, the predicted structure was almost entirely linear 
with a terminal stem loop.  In fact, the only observed difference between the predictions 
was a variation in the size of the stem and loop with the hRSV structure being larger.   
 
 
Additionally, similar NNS viral promoters were run through the software for the purpose 
of noting conservation of features in a larger context. The viruses selected were PIV5, 
another paramyxovirus from a different subfamily and the rhabdovirus VSV.  The 
predicted RNA folds for the trailer promoters were similarly disparate when compared to 
those of HMPV and RSV (Figure 3.7A).  Interestingly, the predicted structure of the 
PIV5 trailer mirrored that of the leaders of Pneumovirinae with a prominent terminal 
stem loop, though the linear portion of the promoter was dramatically shorter.  The VSV 
trailer, however, was predicted to take on a completely novel fold relative to the selected 
paramyxoviruses, featuring a short stem and large loop with the remaining RNA adopting 
a circular pattern.  Overall, the predicted folds from both viruses displayed a sufficient 
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degree of similarity such that it still remained plausible that either promoter could be used 
with HMPV or hRSV to initiate RNA synthesis. 
 
When analyzing the leader RNA folding predictions for PIV5 and VSV, the only 
similarity between these and the pneumoviruses was the presence of some linear 
character, and even the extent of that characteristic varied greatly (Figure 3.7B).  The 
PIV5 leader was predicted to have a much larger stem loop with an additional stem 
within the loop while the VSV leader was predicted to have a small loop in the middle of 
its linear RNA fold. 
 
 
Minireplicon constructs with various promoters synthesized are functional.   
HMPV-based minireplicon systems were based upon the hRSV luciferase construct 
plasmid provided by Dr. Richard Plemper at Emory University.  This vector, which 
contained both RSV promoter sequences with specific endonuclease sites at either end of 
each, also served as an internal control.  HMPV CAN97-83 trailer and leader cDNA 
sequences were obtained via RT-PCR and synthesized with restriction endonuclease 
recognition sequences at their termini.  After subcloning into the hRSV base vector, there 
were a total of four constructs—two homotypic and two heterotypic.  The former group 
contained trailer and leader sequences derived from the same virus, either HMPV (MPV) 
or the hRSV (RSV) internal control (Figure 3.8A).  The heterotypic constructs were 
modified from the base vector at only one promoter such that they contained an HMPV 
trailer (H-trailer) or leader (R-trailer).   
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Preliminary optimization tests were conducted in which several variables were adjusted.  
These included incubation time, which was tested at 12, 24, 36 and 48hpt as well as 
sample size, using different size well plates.  Additionally, luminometer settings were 
varied in the endpoint assay before settling upon a 30sec integration period for all assays.  
Overall, the results suggested that all constructs were functional. 
 
Treatment of minireplicon constructs with different viral stocks exhibit differential 
activities.   
Each of the synthesized constructs displayed luciferase activity significantly above 
background when transfected into BSR cells followed by infection with rgHMPV, rgRSV 
or PIV5-GFP viral stock.  Conversely, transfection of the plasmids followed by infection 
with the rhabdovirus VSV was unable to drive transcription at appreciable levels.  This 
result is in contrast with findings when co-transfection with RSV-specific plasmids for 
the N, P, L and M2-1 proteins elicited a much more variable signal in all constructs tested 
(Figure 3.8B).  These results suggest that all paramyxoviruses can drive transcription 
though not VSV while other factors are likely modulating levels of expression. 
 
 
PIV5 L but not RSV L exhibits complementation with HMPV N and P in the 
minireplicon assay.  Despite the synthesis of two HMPV L gene constructs (one codon-
optimized), no enzymatic activity was detected in this assay despite an association with 
HMPV P.  As such, complementation with the other HMPV RNP proteins and other 
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paramyxoviral large protein plasmids was attempted.   hRSV and PIV5 were selected 
given the previous results showing the ability of these viruses to drive the HMPV 
leader/trailer minireplicon.  While hRSV L could not complement with any combination 
of HMPV N, P, P-FLAG and M2-1 to drive transfection above background levels, PIV5 
L was able to give a signal that was approximately 2-7 fold above background levels 
(Figure 3.9).  This result suggests that the large polymerase of PIV5 may be more similar 
to HMPV L with regard to binding the promoter regions relative to the RSV L protein.   
 
Addition of the RSV 36-nucleotide terminal trailer sequence (TTS) to the HMPV 
promoter creates a more RSV-like RNA fold.  Given the similar predicted folds for the 
RNA trailers for both HMPV and RSV, I hypothesized that addition of the 36 residue 
trailer terminal sequence (TTS) of the RSV promoter, the deletion of which had been 
previously shown to be deleterious to RNA synthesis in that system [85], may improve 
the promoter strength of the HMPV trailer (Figure 3.10A).  Doing so could have had an 
effect on luciferase expression, as more efficient replication could increase the amount of 
minigenomes present for gene expression.  It was first imperative to determine that the 
RNA fold was predicted to resemble that of the RSV trailer, so the constructs’ sequences 
were imported into the SplicePort RNA prediction software.   
 
The prediction software analysis suggested that the HMPV-TTS combination more 
greatly resembled the RNA fold of hRSV than that predicted for HMPV alone (Figure 
3.10B and C).  However, this was only the case when the 30 nucleotide linker sequence 
between the TTS and the region with homology to HMPV was also incorporated.  These 
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predictions, along with previous minireplicon data, suggested that addition of the entire 
TTS and linker, which represent the first 66nt of the RSV trailer, may make the HMPV 
constructs more robust in their reporter gene expression. 
 
RSV terminal trailer sequence confers greater transcriptive activity to HMPV 
minireplicon constructs.   
Synthesis of the new vectors began with construction of custom primers that added first 
the linker cDNA sequence and the TTS in two mutagenesis-like PCR insertions.  These 
constructs were then tested in the same minireplicon assay.  The H-trailer(TTS) vector 
was able to drive expression at levels similar to those of the RSV plasmid.  In contrast, 
the H-trailer plasmid elicited roughly a third of the luciferase expression of the RSV 
plasmid under the same conditions.  The homotypic MPV plasmid also exhibited greater 
luciferase activity when its trailer had been modified relative to the unmodified construct.  
In contrast, the addition made no significant difference when the plasmids were co-
transfected with PIV5 RNP plasmids (N, P and L) (Figure 3.11).  Overall, these results 
suggest that the RSV TTS sequence is sufficient to increase luciferase expression to 
equivalent levels between HMPV and hRSV. 
 
Summary 
The work within the minireplicon has provided unique insights on the poorly understood 
mechanism underlying viral gene transcription.  Given these data, it is likely that RNA 
folding, predicted for several different viruses in this study, is playing a large role in the 
regulation of viral gene transcription.  Further, there appears to be a difference in the 
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level of selectivity of viral polymerases though all paramyxoviruses may be able to drive 
a minimal level of transcription given an HMPV or hRSV promoter.  There also appears 
to be some level of complementation possible between different paramyxoviruses, which 
is suggestive of conservation within areas of the different large proteins.  However, no 
report examining such conservation has yet been conducted.  Finally, both the role of 
RNA folding in viral gene transcription and the greater potential selectivity of the hRSV 
RdRp are supported by the data showing that the HMPV trailer becomes a better inducer 
of RNA synthesis with the addition of the hRSV-specific TTS.  Altogether, this work 
represents a solid beginning to research in an area that is not well characterized in NNS 
biology.   
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Subsection III:  HMPV Assembly Project 
 
Having observed the underlying complexities that regulated the pH-dependent fusion 
activity of HMPV and gained insight into the dynamics of promoter activity for the virus, 
this work had successfully provided insights into early events governing the HMPV 
infection process.  In order to attain a more complete understanding of this pathogen, 
however, one must explore the temporal and spatial relationship between these early 
events and the cellular processes governing later ones in the infected cell, namely viral 
particle assembly and egress. 
 
These studies specifically focus on the dynamic association between two viral proteins 
that are indispensible in bridging the gap from RNA synthesis to progeny virus 
dissemination.  As the nucleocapsid protein performs its chief role as a viral RNA 
chaperone, it must be able to associate with the phosphoprotein in its role as a polymerase 
cofactor; however, this association must also be less transient as these two proteins are 
intimately linked along with the viral polymerase and genomic RNA in the packaged 
virus particle.  As such, the best investigative tool available was a timecourse study to 
demonstrate how these two factors differentially distribute throughout the course of 
infection.  From there, one can begin to piece together function from localization and the 
aid of additional assays. 
 
 
 
55 
 
HMPV nucleocapsid and phosphoprotein interact variably in the presence and 
absence of infection 
It has been previously reported that HMPV N and P co-localize to cytoplasmic inclusion 
bodies, which can be detected both during infection and transient expression [30]. 
However, that same report found that a detectable interaction was observed 
biochemically only in the case of infection.  We sought to further examine the interaction 
among proteins required for HMPV RNA synthesis using co-immunoprecipitation assays. 
These experiments included the HMPV nucleocapsid, large polymerase, and 
phosphoprotein as well as a recombinant form of HMPV P harboring a DYKDDDDK 
epitope tag at its carboxyl terminus immediately following the final amino acid of the 
polypeptide (P-FLAG). 
 
After transfection of A549 cells with various DNA constructs, the cells were then either 
infected or mock infected for 24 hours prior to metabolic labeling.  Immunoprecipitations 
were then performed using an antibody to HMPV P.  The results showed that HMPV P 
can pull down HMPV L in the presence or absence of infection, though additional forms 
of the polymerase appear to be detected in infected cells (Figure 3.12A and B).  It should 
be noted that HMPV L can only be detected when transfected, likely due to low copy 
number within infected cells.  The polymerase was also found to co-immunoprecipitate 
with HMPV P-FLAG, suggesting that the additional of the epitope tag did not affect the 
ability of the protein to bind a major interacting partner (Figure 3.12C).  Due to the 
presence of an apparent background band of similar size to WT P when lysates were 
probed with the FLAG antibody, any potential co-immunoprecipitation between P-FLAG 
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and HMPV cannot be assessed.  Further, the necessity of 10% polyacrylamide gels for 
proper migration of HMPV L meant that HMPV P and any HMPV N that may have co-
immunoprecipitated could not be resolved.  
 
To address this we employed a different approach to clarify the potential N-P interaction 
within cells.  Cells were infected for either 6 or 24 hours, and immunoprecipitations with 
antibodies to HMPV P or the FLAG tag were performed.  HMPV N that had co-
immunoprecipitated was then assayed by western blotting.  An interaction between 
HMPV N and P was not detected in uninfected cells, but interactions were observed at 6 
hours post infection (hpi) with and with a greater amount of N observed at 24hpi (Figure 
3.13A). This finding is consistent with a previous study [30].  In contrast, HMPV P-
FLAG was found to be associated with HMPV N in the presence or absence of infection.   
 
While it had appeared that P-FLAG and WT P were equivalent in the overexpression and 
radiolabeling studies, we wished to exclude the possibility of large variation in the 
amount of protein present between those cells transiently expressing N, P or P-FLAG and 
those that had been infected.  As such, we performed western blotting analysis of each of 
these three proteins from cells that had been transfected overnight or infected for 24 
hours (Figure 3.13B).  There was virtually no difference between HMPV N levels when 
transfected or from infected cells with a difference of only 0.2% (Figure 3.13C).  When 
transiently expressed, HMPV P levels were increased by 74% over infection.  This level 
of expression was slightly higher than that co-expression of HMPV N and P.  
Interestingly, the level P-FLAG was also lower than that of WT P.  Given these results, it 
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is likely that any observed variation in the interactions between these proteins is not due 
to drastic changes to expression levels under different conditions. 
 
Overexpression of HMPV phosphoprotein results in alterations to morphology of 
the infected cell 
I next sought to determine the cellular effects of expression of each of these proteins.  
Following transfection of A549 cells, we observed that HMPV N expressed alone was 
distributed throughout the cytoplasm; however some local areas of concentration were 
observed (Figure 3.14A).  Interestingly, while either HMPV P or P-FLAG was detected 
throughout the cytosol, there was an apparent concentration of protein at the cellular 
periphery (Figure 3.14B-C).  Further, HMPV P and P-FLAG were readily detected in 
filamentous processes at the periphery of these cells.  Such extensions have been 
described as a characteristic of infection with RSV, though the particular constituents of 
such structures seem to vary between viruses [71].  These results suggest that the P 
protein may contribute to the formation of these structures.    
 
We next explored how co-expression of HMPV N and P affects protein distribution.  It 
has been previously reported that the HMPV N and WT P proteins co-localize to 
cytoplasmic punctae similar to the inclusion bodies observed during infection [30], and 
we observed a similar result (data not shown).  Expression of HMPV P-FLAG with 
HMPV N resulted in high levels of observed co-localization (Table 3.2); however, unlike 
with WT P, there were no observed inclusions formed by the proteins.  HMPV N was 
now exhibited increased presence at the periphery, similar to the localization of P-FLAG 
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alone (Figure 3.14D-F).  One additional difference between cells expressing P-FLAG 
alone and those co-expressing HMPV N was the induction of apparent membrane 
blebbing.  Interestingly, these rounded structures were observed at the periphery of cells 
only where both HMPV N and P-FLAG were both present.  This suggests that the 
interaction between these two viral proteins may be sufficient to curve membranes or 
form structures akin to those of viral particles under these conditions.   
 
HMPV infectious particle detection coincides with shift in viral protein distribution 
during infection 
Given the findings with P-FLAG and HMPV N localization, we sought to compare that 
to that of HMPV N with WT P in the context of infection.  We conducted a time course 
study of these proteins at 6, 12, 24 and 48hpi to note how their relative localization 
changed over time.  At the earliest point, 6hpi, discernible punctate structures were 
apparent, but co-localization between the two proteins was sporadic and potentially 
consistent with ongoing translation (Figure 3.15B).  Interestingly, these nascent 
polypeptides were primarily perinuclear in their distribution.  As infection proceeded and 
protein expression increases, HMPV P was observed throughout the infected cell at 
12hpi.  The P protein was observed within perinuclear inclusions with HMPV N and at 
the cellular periphery in filaments.  By contrast, N remained concentrated within punctate 
bodies, some without HMPV P (Figure 3.15C).  
 
As microscopy indicated a large increase in phosphoprotein between 6 and 12hpi, we 
conducted metabolic radiolabeling experiments at the same time points to determine the 
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amount of HMPV P (and P-associated nucleocapsid) present.  Consistent with the 
microscopy, P and co-immunoprecipitated N proteins were only faintly observed at 6hpi 
while a marked increase in protein was observed by 12 hours (Figure 3.16).  
 
By 24 hours, both N and P appeared more diffuse than earlier while the cytoplasmic 
inclusion bodies containing both proteins were dramatically larger than previously 
observed (Figure 3.15D).  Notably, HMPV N was also partially present at the periphery 
of the cell.  While HMPV N appears to be present either only at the periphery or within 
inclusions, HMPV P is still observed throughout the cytoplasm in addition to within 
inclusion bodies.  At 48hpi, cytoplasmic bodies persisted but were morphologically 
distinct from those seen earlier as less HMPV N was observed at their centers (Figure 
3.15E).  Further, HMPV P appears to be all but excluded from these bodies with 
relatively smaller amounts detected only at their edges.  More globally, HMPV P 
appeared much more diffuse than the more condensed distribution of HMPV N.   
 
HMPV N and P move about the infected cell independently of one another 
Our results suggested that the localization of HMPV N and P changed throughout the 
course of infection.  To assess the role of the cellular microtubule network in HMPV N 
and P motility, infected A549 cells were treated at 9hpi with 7µg/ml nocodazole or 
vehicle control (DMSO).  Infection continued in the presence of the drug for a total of 12 
or 24 hours.  While both HMPV P and HMPV N were observed within punctate and 
filamentous distributions at 24hpi without nocodazole treatment (Figures 3.17C-D), 
disruption of microtubules completely ablated the peripheral localization for HMPV N 
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specifically (Figures 3.17F and 3.17H).  Additionally, propagation of HMPV in the 
presence of nocodazole resulted in titer reduction of greater than one order of magnitude 
(Table 3.3).  This result suggests that HMPV N is translocating from inclusions in a 
microtubule-dependent manner.  Further, as HMPV P localization was not drastically 
affected by the drug (Figure 3.17E and 3.17G), it also suggests that HMPV N and P move 
to the periphery of the cell via different mechanisms. 
 
To shed light on the correlation between HMPV N and P translocation and virus 
assembly, we conducted an egress assay to assess viral particle budding from infected 
cells at the same time points as our microscopy studies.  Supernatants of infected cells 
were assayed for HMPV P content following purification by centrifugation on a 20% 
sucrose cushion.  HMPV particles were barely detected at 24hpi but readily observed at 
48hpi, suggesting that viral assembly and budding occur at these times (Figure 3.18).  
These data show that detectable egress is temporally consistent with the peripheral 
localization of HMPV N and P at the cellular periphery, suggesting this translocation may 
have a role in HMPV assembly. 
 
Localization of newly synthesized HMPV RNA is consistent with that of the 
nonstructural proteins throughout infection 
i next wished to determine if synthesized RNA followed a similar distribution to HMPV 
N and P throughout infection.  To do so, I utilized 5-bromouridine labeling, which has 
been employed only in non-paramyxoviral systems, such as vesicular stomatitis virus 
[47].  Again, the labeling periods were consistent with the time points previously 
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established at 6, 12, 24 and 48hpi.  At the earliest point, we observed RNA in perinuclear, 
punctate structures of similar scale to those containing HMPV N and P at the same period 
(Figure 3.19B).  By 12hpi, a more diffuse, yet still tightly perinuclear, pattern of RNA 
distribution was observed (Figure 3.19C).  This perinuclear location is consistent with 
that of inclusion bodies containing HMPV N and P at 12hpi (Figure 3.15C).  
Interestingly, the RNA was still detected within somewhat punctate areas at this point as 
well.  At 24hpi, a more diffuse pattern was observed (Figure 3.19D).  This apparent 
spreading of RNA was similar to what was seen in viral proteins, particularly HMPV N, 
at this point during infection.  By 48hpi RNA was still observed in punctate bodies 
though they appeared small and diffuse throughout the infected cell.  This is also 
consistent with the viral protein time course in that some morphological distinction was 
observed relative to earlier times.  Also RNA was present within filamentous extensions 
that were morphologically similar to those that had been observed to be concentrated 
with HMPV P (Figure 3.19E).  This result suggests a potential role for these filaments in 
viral budding as this was the same period when egress was robust.  Overall, these data 
suggest that the RNA-rich punctate bodies observed at early time points in the time 
course may be the same as the cytoplasmic inclusions containing HMPV N and P.  By 
extension, the results would be consistent with such inclusion bodies as sites of RNA 
synthesis during HMPV infection. 
 
Summary 
The data presented in this subsection serves to underscore the spatial link between viral 
RNA synthesis and particle assembly.  It was found that proteins necessary for genomic 
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replication and gene transcription displayed similar localization to newly synthesized 
viral RNA to a large degree, particularly HMPV N.  This finding, along with the fact that 
expression of HMPV P, either alone with HMPV N, can imitate much of the cellular 
morphology of an infected cell at the later stages of infection with the concentration of 
proteins within filamentous extensions, suggests that there is a high level of coordination 
between the two processes.  Further, there are indications of the underlying mechanism 
orchestrating this process, as HMPV N, at least, seems to be affected by the disruption of 
microtubules.  However, the fact that such disruption only decreases, but does not ablate, 
viral growth is consistent with a much more complex system linking the RNA synthesis 
to packaging and egress both spatially and temporally during HMPV infection. 
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Table 3.1.  Estimated distances between -carbons of selected amino acid residues in 
F2 in the HMPV F homology model 
The table lists the approximated values between the -carbons of amino acids within the 
CBF2 and HRA regions of HMPV F.  All values are based upon the homology modeling 
done based on the crystal structure of PIV5 F in the prefusion form.  The distances, listed 
in angstroms, allow for an estimation of the likelihood of salt bridge formation between 
these adjacent residues.  This table was prepared with Dr. Andres Chang. 
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Table 3.2. Analysis of co-localization between transiently expressed HMPV N and P-
FLAG.  
The table shows the calculated co-localization coefficients for immunofluorescence 
assays following transfection of HMPV N and P-FLAG into A549 cells. The samples 
selected are from three different experiments (1 and 3, 4 and 5 or 6 and 7). The Pearson 
coefficient measures co-localization after adjustment for intensity between two channels 
and is the slope of the line of a plot of relative fluorescent intensities of the channels 
examined. The range for this value ranges from 0 (exclusion) to 1 (full co-localization). 
The Manders coefficients (M1 and M2) are taken as fractions of overlap between given 
channels. In this instance, M1represents the portion of all N that overlaps with P-FLAG. 
M2 stands for the fraction of P-FLAG overlapping with N in each field. These data were 
generated with aid of the JACOP plugin within the ImageJ software application. 
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Table 3.3. Results of HMPV propagation in the presence or absence of nocodazole.  
 
Recombinant HMPV expressing GFP was initially propagated as described with 
incubation of the virus on A549 cells for 2 hours prior to washing. Prior to the addition of 
propagation medium, the volumes of OptiMEM + L-glutamine were treated with either 
7μg/mL nocodazole in DMSO or an equal volume of vehicle. Cells were treated daily 
with TPCK trypsin until cytopathic effects were evident. Virus was harvested from cells 
and tittered by serial dilution followed by fluorescent counting. The nocodazole-treated 
cultures exhibited a reduction in titer greater than one order of magnitude or 
approximately 27-fold. 
 
  
66 
 
 
 
 
 
Figure 3.1. HMPV F CBF2-HRA alanine mutants all express near or above WT 
levels. 
 Following alanine scanning site-directed mutagenesis of HMPV F, the constructs were 
transfected into Vero cells and assayed for protein presence at the cell surface 24 hours 
post transfection via surface biotinylation.  (A) Results of experiments normalized to WT 
expression for both total and surface expression show that only E51A is reduced in its 
expression while all other mutants are at or above WT.  (B) A representative gel showing 
the relative expression of the synthesized CBF2-HRA mutants.  Dr. Andres Chang and I 
contributed evenly to the work in this figure, each doing the assays multiple times and 
combining the results.  
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Figure 3.2. HMPV F CBF2-HRA mutants exhibit varied levels of fusogenic activity. 
 (A)  Fusion activity was assessed by syncytia assay where all mutants save E51A were 
shown to be fusogenic at pH5 with D54A and E56A displaying larger syncytia than WT.  
At pH 6 these more fusogenic mutants were also able to mediate membrane fusion.  
Images are representative of greater than three separate experiments.  (B) A luciferase 
reporter gene assay was used to measure the fusogenicity of each mutant and agreed with 
the syncytia results, showing D54A and E56A to be hyperfusogenic and E51A to be 
incompetent to mediate cell-cell fusion.  Dr. Andres Chang and I contributed evenly to 
the work in this figure, each doing the assays multiple times and combining the results.  
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Figure 3.3. Substitution of E51 leads to alterations in HMPV F proteolytic 
processing. 
 (A) Representative gel showing the surface expression of HMPV F mutants and (B) 
quantification of the amount of cleaved protein in the presence and absence of trypsin.  
Both E51A and E51K mutants were shown to be cleaved at roughly twice the levels of 
WT without trypsin cleavage, suggesting a greater sensitivity to aberrant proteolysis.  Dr. 
Andres Chang and I contributed evenly to the work in this figure, each doing the assays 
and combining the results. 
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Figure 3.4. Combined mutagenesis of H435 and F2 residues affect protein stability. 
Total and surface expression of HMPV F mutants was performed and showed that while 
combination of the hyperfusogenic mutations H435R and either D54A or E56A did not 
affect protein expression, combining the two F2 mutations or all three mutations did 
result in lower detection of protein levels.  However, substitution with the isosteric 
residues served to stabilize the protein relative to the alanine mutants in all cases.  An 
E51K mutation with or without H435R also exhibited a marked reduction in expression.  
Dr. Andres Chang and I contributed evenly to the work in this figure, each doing the 
assays multiple times and combining the results.  
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Figure 3.5. Combinatorial mutagenesis of different regions of HMPV F result in 
alterations to fusion activity. 
 (A)  Reporter gene fusion assay and  (B) syncytia assay results at pH 5 show that 
combination of hyperfusogenic (D54A/H435R, E56A/H435R) or stabilizing mutations 
(D54N/E56Q, D54N/E56Q/H435R) promoted fusion at higher levels than WT while 
those that destabilized surface expression (D54A/E56A and D54A/E56A/H435R) all 
were sub-WT in their fusion activity at all pH levels also.  Smaller syncytia form for the 
stabilizing mutants.  Dr. Andres Chang and I contributed evenly to the work in this 
figure, each doing the assays multiple times and combining the results.
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Figure 3.6. Comparison of HMPV and RSV RNA promoter fold predictions. 
RNA sequences for HMPV and RSV were imported into the SplicePort RNA folding 
predicton software.  The folds that were predicted to be the most thermodynamically 
favorable were assessed relative to each other.  (A)  The trailer promoters exhibit some 
similarities in their general fold though the RSV trailer is significantly longer than that of 
HMPV.  This extra length appears to result in a self-folding terminal region.  (B)  The 
leader promoters are much more similar, featuring a mostly linear RNA with a single 
terminal stem loop. 
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Figure 3.7.  Other NNS viral promoters are predicted to differ from HMPV and 
RSV. 
Sequences corresponding to the promoter sequences for both PIV5, a paramyxovirus, and 
VSV, a rhabdovirus, were entered into SplicePort to determine the similarity of the 
predicted folds to HMPV and RSV.  (A) The trailer for PIV5 is more reminiscent of the 
pneumovirus leaders with its terminal stem loop and short linear sequence while the VSV 
trailer has a unique relative to either of the predicted trailer promoters from the members 
of Pneumovirinae.  (B)  The VSV leader features a predominantly linear arrangement 
with a single loop, which may be more similar to HMPV and RSV than the PIV5 leader, 
which features a stem loop stem structure and very little linear character. 
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Figure 3. 8.  Different promoter combinations vary in their ability to drive viral 
transcription. 
(A) Catalog of the synthesized minireplicon vectors.  The arrows show the order in which 
each plasmid was created from the RSV plasmid by the replacement of hRSV promoter 
sequences with those of HMPV.  (B)  In the minireplicon assay, the most expression of 
the reporter product was consistently observed with those constructs with an RSV 
promoter at 24 hours post transfection/infection.  The loss of the RSV leader, however, 
seemed to be less deleterious than that of the trailer, suggesting a large role for that 
promoter in the assay.  Interestingly, any paramyxovirus was capable of driving roughly 
equal amounts of gene expression while VSV was not able to promote expression for any 
construct. 
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Figure 3.9.  PIV5 L is able to complement other HMPV RNP components. 
(A) The minireplicon assay was used to establish what viral polymerase, if any, could 
complement for the loss of HMPV L.  While RSV L did not exhibit any expression above 
background levels, PIV5 L was able to promote luciferase activity in concert with HMPV 
N and P or P-FLAG at levels comparable to that of PIV5 N, P and L. (B) An inset of the 
same data as in A to better illustrate the effects of the complementation. 
 
  
75 
 
 
 
 
 
 
 
Figure 3.10. Predicted RNA folding of the HMPV trailer mimics that of the hRSV 
trailer with the addition of the TTS. 
SplicePort renderings of RNA folding predictions for (A) the hRSV trailer terminal 
sequence (TTS), (B) HMPV trailer with the TTS and its linker and (C) hRSV trailer are 
shown.  These demonstrate the similarity between the predicted fold of the two promoters 
when the HMPV trailer is modified.  The addition of the TTS did not appear to 
dramatically alter the folding of the rest of the HMPV trailer relative to the previous 
predictions without this modification. 
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Figure 3.11. Addition of TTS to HMPV minireplicon promoters significantly 
increases luciferase activity. 
When the 36nt TTS from the RSV trailer (along with its requisite linker region) is added 
to the HMPV trailer in either the homotypic or heterotypic plasmid, viral transcription 
activity as assessed by luciferase activity markedly increases. In the case of the H-trailer 
plasmid, such an addition makes no significant difference between the construct and the 
RSV homotypic plasmid. 
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Figure 3.12. Different interactions are observed for HMPV P constructs in the 
presence and absence of infection. 
 
 (A) A549 cells were transfected with plasmids encoding the HMPV construct denoted 
above each lane before proteins and metabolically labeled with 35S before 
immunoprecipitation with either HMPV P or FLAG antibody. (B-C) Cells were 
transfected as before then infected at 24hpt prior to radiolabeling.  Samples were assayed 
with either HMPV P or FLAG antibody.   
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Figure 3.13. HMPV N and P-FLAG interact irrespective of cellular infection state. 
(A) A549 cells were transfected plasmids encoding the HMPV construct denoted above 
each lane.  At 24hpt, cells were either infected with HMPV (MOI=5) or mock infected 
for the amount of time indicated.  Samples were then immunoprecipitated with an HMPV 
P antibody, and the bound fraction was blotted with an HMPV N antibody.  (B) A549 
cells were either infected with HMPV (MOI=5) or transfected with HMPV plasmid 
constructs.  At 24hpt, samples were blotted for HMPV N or P.  Gels are representative of 
three independent experiments.  (C) Quantification HMPV protein levels normalized to 
alpha-tubulin expression from same lysates. 
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Figure 3.14. HMPV phosphoprotein concentrates at cellular periphery and in 
filamentous extensions. 
A549 cells were transfected with 2.5ug pCAGGS plasmid DNA encoding the HMPV 
(strain CAN97-83) construct denoted below each panel (A-C).  (D-F) A549 cells 
transfected with equal amounts HMPV N and HMPV P-FLAG pCAGGS constructs.  
Cells were imaged at 30 hours post transfection.  Images are representative cells from no 
less than three separate experiments.  Arrows point to concentrations of protein within 
filamentous extensions of each cell.  
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Figure 3.15. The distribution and co-localization of HMPV N and P varies within 
infected cells over time. 
(A-E) A549 cells were infected with HMPV (strain CAN97-83) at an MOI of 5 for 
variable lengths of time (6-48h) prior to being fixed with 4% formaldehyde and 
processed for confocal microscopy.  Images displayed are representative of at least three 
independent experiments.  Arrows indicate protein with filamentous extension.   
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Figure 3.16. HMPV P levels markedly increase between 6 and 12 hours post 
infection.  
A549 cells were infected with HMPV (MOI=5) for various lengths of time with 35S 
radiolabeling occurring at 1hpi through the end.  Cells were then lysed to detect the 
amount of HMPV P and N that had been synthesized over the specific period. 
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Figure 3.17. HMPV HMPV N and P translocate to the cellular periphery 
independently by 24 hours post infection. 
 (A-H)  Confocal microscope Z-stack renderings of A549 cells infected with HMPV for 
the indicated length of time.  In all cases, either DMSO or 7µg/ml nocodazole was added 
at 9hpi before allowing infection to proceed to end of time point. 
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Figure 3.18. HMPV N and P peripheral transition temporally corresponds to viral 
egress. 
A549 cells infected with HMPV (MOI=5) or mock infected for the amounts of time 
indicated.  Cellular supernatants were then collected and centrifuged on a 20% sucrose 
cushion before being reconstituted and blotted with an HMPV P antibody.  Work in this 
figure was done by Farah El-Najjar.  
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Figure 3.19. Labeled nascent RNA within HMPV-infected cells undergoes changes 
to its distribution similar to those of the non-structural proteins. 
 
BSR cells were infected with HMPV (strain CAN97-83) at an MOI of 5 for variable 
lengths of time (6-48h), with the latter portion of that period being used to starve cells of 
uridine (2h) and label newly-synthesized RNA over a 3h interval with 5-bromouridine.   
Infection was ended with fixation before samples were processed for confocal 
microscopy.  Nascent RNA is colored in red while nuclei, stained with DAPI, are colored 
cyan. 
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Chapter IV:  Discussion 
 
Subsection I:  HMPV Fusion 
 
The experimental results of these studies have demonstrated that processes governing the 
triggering of the HMPV fusion protein are even more complex than had been originally 
hypothesized.  Specifically, the results showed that at least two regions within the 
metastable prefusion form influence this event.  However, not even relaxing the 
constraints of both of these regions were sufficient to alleviate the necessity of low pH to 
induce the conformational change associated with HMPV fusion activity.   
 
Studies of paramyxoviral fusion were buoyed significantly with the crystallization of 
PIV5 F in its prefusion form.  The protein was stabilized with use of GCN4 tags 
replacing the transmembrane domains, and this allowed for some of the first structure-
function studies of fusion proteins within this viral family [35].  Consequently, a block of 
residues within the F2 region with conservation between PIV5 and Hendra virus F 
proteins was identified that demonstrated effects on the stability of the fusion protein 
when mutated.  These effects were attributed to the modulation of the triggering of fusion 
[45].  However, it was not until a pH-dependent triggering mechanism for a 
paramyxovirus was found that this region’s contribution to triggering fusion as opposed 
to other processes during the event could be tested [23].   
 
These results show that HMPV F (CAN97-83) exhibits an enrichment in charged residues 
within this very region.  As such, the ensuing mutagenesis studies that implicated CBF2 
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as a regulator of HMPV F triggering are very much in agreement with previous work in 
the field.  In fact, the results of the two studies mirror each other on the face of issue with 
both studies identifying mutations that exhibit either hypo- or hyperfusogenic 
phenotypes.  Further, they both support the overall view of the field in that metastability 
is by and large controlled by the trigger of fusion.  Delving even more deeply into the 
data, some of the findings in this work are entirely consistent with the other study.  The 
idea that HMPV F isosteric mutations could, at least, attenuate the effects of a 
hyperfusogenic mutant with a presumed promiscuous trigger (e.g. D54N/E56Q/H435R) 
being a prime example.  In that report, the authors concluded that side chain density 
played a role in the maintenance of optimal metastability in that an alanine substitution at 
I49 in PIV5 F resulted in an increase in fusion.  The results reported here only go to 
underscore that this conservation observed between PIV5 and Hendra likely applies to a 
wider portion of Paramyxoviridae, at least as far as HMPV. 
 
It is important to note that while I have implemented studies using the CAN97-83 strain 
of HMPV, which has been demonstrated to fuse in a pH-dependent manner, some argue 
that this is merely an anomaly among paramyxoviruses.  In fact, it has been published 
that only a small number of known HMPV strains with Clade A exhibit greater fusion 
activity at reduced pH [24].  However, this argument is based, in part, upon the fallacy 
that all isolated strains of the virus currently available for research purposes mimic the 
population of virus strains at large.  This is simply not the case.  In fact, it is far more 
likely that a large number of clinically relevant strains are not available as such, given the 
observed differences between lab strains and newer clinical isolates for many viruses.  To 
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that end, any suggestions as to the abundance of strains that present a particular activity 
are hasty, at best.  Further, the authors of this work tested only five strains (one from each 
known clade and two from A2), showing that both their selected A1 strain and one of the 
two A2 strains tested (CAN97-83) exhibited the very activity that they go on to 
categorize as rare.  In any event, the true value of a strain like the one used in these 
studies is that questions regarding the steps regulating the fusion process can be more 
carefully examined as there are both permissive and restrictive conditions under which 
we can test these hypotheses. 
 
Among the discoveries facilitated within this system was the role of H435 in HMPV F-
mediated fusion [25].  It was found that when H435 is mutated to alanine, fusion is 
drastically reduced.  Interestingly, this particular histidine was only one of several that 
were examined for a role in HMPV F fusion.  The underlying hypothesis was that this 
histidine was working in concert with surrounding positively charged residues to 
modulate triggering.  This work also established H368 as an effector of HMPV F activity.  
This latter point was then expanded upon by another group, which in addition to 
implicating these histidine, examined the contribution of some of the adjacent positively 
charged residues [26].  Alanine scanning showed these residues to have an effect on 
triggering and to be fully consistent with the results reported here. 
 
In fact, the results of these studies, while consistent with these reports in the field, allow 
for a much more complete picture of the complexities that are associated with HMPV F 
triggering.  The findings show that while charge-charge interactions certainly play a role 
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in area around H435, the overall data suggest that both electrostatic and steric interactions 
are involved.  Specifically, results showed that H435E or H435D mutations, a mimic for 
a protonated histidine, could ablate the ability of triggering, likely through the 
stabilization of interactions between H435 and some combination of K295, R396, and 
K438 [27].  However, the data also shows that isosteric mutations in F2, namely at D54 
and E56, can stabilize the protein as measured by cell surface expression.  Taken 
together, this suggests a system in which triggering has no one on/off switch but rather a 
series of lynchpins that must be released in order to allow triggering to occur.  To that 
end, it would appear that the necessity of low pH would likely only impact the 
electrostatic interactions but not others regulating this event. 
 
To add yet another layer of complexity to HMPV fusion and entry, this virus has been 
reported to be equally infectious without its attachment protein [28].  This stands in stark 
contrast to the vast majority of paramyxoviruses, which are thought to need contacts 
between the fusion and attachment proteins to trigger fusion [86-88].  One can infer that 
such an obligate interaction between these proteins would minimize the amount of 
premature activation of fusion in these systems, essentially ensuring that attachment 
precedes triggering.  In the absence of such a requirement, such as for HMPV, the need 
for some regulation of triggering within the protein itself becomes all the more crucial.  
As such, the pH dependency and multiple regions contributing to the control of this event 
for HMPV F would be a logical, expected outcome given the data presently accepted by 
the field. 
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Subsection II:  HMPV Minireplicon 
 
As many interesting questions that have arisen from the results of the work on the fusion 
protein, there may be even more conjecture surrounding the minireplicon project and 
HMPV promoter activity particularly.  The results showed that there was a significant 
difference in the amount of transcription being driven by either hRSV promoter relative 
to that of HMPV; however, there may be some bias in the system given the subcloning 
techniques used to create the constructs.  Further, I observed that any tested 
paramyxovirus was capable of driving roughly equivalent expression from any given set 
of promoters, suggesting that all within the family may have a degree of conservation 
with regard to polymerase-promoter interactions.  On a similar note, the HMPV N and P 
plasmids were shown to be able to drive some RNA synthesis in concert with PIV5 L but 
not hRSV L, which again may be demonstrating conservation in particular domains of the 
RdRp.  The results of this work certainly demonstrate that this interaction between the 
viral promoters and the proteins responsible for HMPV RNA synthesis warrant further 
study.  These experiments would serve to further explain the ability of paramyovirus 
replication components to be interchanged. 
 
With regard to paramyxovirus promoter activity as a director of RNA synthesis, hRSV 
stands out as an exemplar due to the inordinate amount of work performed over more 
than a decade with this particular virus.  For instance, it has been shown that there is little 
difference between the leader and trailer promoters’ abilities to drive RNA synthesis and 
that different nucleotides are required specifically for normal levels of either transcription 
or replication [68, 89].  Some of these moieties included 1U, 2G, 6U, and 7U for 
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replication (trailer promoter) or 3C, 5C, 8U, 9U, 10U, and 11U for transcription (leader).  
It is likely that similar results would be observed in HMPV as all these nucleotides in 
both the trailer and leader promoters are conserved.  In fact, the one similar study 
examining the promoter activity of HMPV specifically did find that 2G was critical for 
maintaining viral replication but not transcription [90].  
 
Bolstered by the similarities between the viral promoters observed in these studies, it 
seemed that the best way to approach questions about HMPV promoter activity would be 
in the context of the much more well-characterized hRSV system.  As such, the 
minireplicon system established for these studies was meant to give comparative results.  
Given that premise of the experiment, the novel finding of hRSV promoters being 
capable of driving significantly greater gene expression relative to HMPV is difficult to 
place in the context of what has been reported in the field.  However, given the myriad of 
similarities between the two pathogens, the discovery of such a difference is quite 
interesting.  What remains unclear is the effect, if any, this difference may have on the 
overall infectious cycle of either virus. 
 
Similarly, the fact that each paramyxovirus was able to equivalently induce transcription 
from a given set of promoters is also quite surprising.  This result was further 
corroborated by the ability of PIV5 L to compensate for the loss HMPV L in the 
minireplicon assay.  This concept of polymerase complementation and minireplicon 
degeneracy has been examined before with different constituents.  In one instance, an 
HMPV minireplicon system was shown to be functional with any member of the 
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subfamily Pneumovirinae, including avian metapneumovirus (AMPV) or hRSV.  
However, bovine parainfluenza virus (PIV3) exhibited no such activity in the system 
[29].  Such a result suggested that there is some level of phylogenetic conservation 
required for RNA synthesis even within the Paramyxoviridae viral family.  Further, 
replacement of the HMPV L gene with that of AMPV L resulted in attenuation of viral 
growth in vivo despite the minireplicon results. 
 
However, a more recent study offers another methodology.  In that work, the large 
polymerase proteins of three different viruses (measles, Nipah and hRSV) were truncated 
at points that had been shown to be tolerant of epitope tag insertions without detriment to 
functionality.  After these protein fragments were synthesized, they were used in different 
combinations to determine the extent of trans-complementation possible between 
different viruses [91].  The authors found that no significant activity when different viral 
polymerase fragments were combined but that most RNA synthetic activity could be 
restored with the combination of homotypic fragments.  Both of these studies seem to 
agree that even relatively phylogenetically similar agents may not be able to combine to 
drive RNA synthesis. 
 
These results make sense insofar as different viruses are considered molecularly distinct 
agents for a reason and, therefore, trans-complementation is not likely.  To that end, it 
would also seem that these studies are in disagreement with the findings reported here.  
However, this is simply not the case.  Firstly, neither of the other reports compared the 
interactions between viral proteins as was done with these studies.  For example, it was 
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shown that PIV5 L, in concert with HMPV P and N, was able to drive some RNA 
synthesis from either the RSV or MPV plasmid at levels roughly equivalent to that of 
PIV5 L, N and P.  Conversely, hRSV L was not able to do so.  This result suggests that 
PIV5 L is more able to interact with HMPV N and P than hRSV L.  Further, it should be 
noted that the authors of the first report mentioned did not directly compare HMPV and 
hRSV, so there is not direct conflict with these results.  There is even a region of PIV5 L 
with greater homology to HMPV L than hRSV L within the polymerase active site (692-
7[HMPV]/720-5[PIV5]).  The significance of this region with respect to template 
recognition, however, is not immediately clear. 
 
The results reported here are also not at odds with those of the more recent study either.  
The overall premise of the authors’ work was that separate domains of the polymerase do 
not function well when derived from different viruses.  While the implications of 
domains within the polymerase polypeptide folding independently are very interesting, it 
does not rule out trans-complementation altogether.  Rather, within the context of my 
work, it is extremely plausible that there are particular intramolecular interactions that are 
specific to each viral RdRp that affect overall functionality.  In that case, substitution of 
the entire protein would be the only way to observe any sort of trans-complementation.   
 
Finally, it is important to not overstate the phylogenetic relationship with regard to 
complementation as other factors, such as varying degrees of selectivity regarding 
template recognition are likely playing a role.  The addition of the hRSV trailer terminal 
sequence (TTS) made the HMPV promoter a much better template for the hRSV 
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polymerase.  This resulted in greater reporter gene expression.  This suggests a certain 
level of specificity for this sequence in the case of this particular viral RdRp.  Such an 
assertion is supported by a recent study of hRSV promoter-driven intiation of RNA 
synthesis.  In that study, initiation was found to vary between two different start positions 
with different, non-templated extensions at the end of the collected antigenomes [92]. 
Analysis of this 3' terminal extension on promoter activity indicated that it can inhibit 
RNA synthesis initiation, indicating that hRSV polymerase-promoter interactions are 
more complex than previously thought and suggesting potentially sophisticated 
mechanisms for regulating promoter activity during infection. 
 
To that end, the other results, in which hRSV L did not exhibit trans-complementation 
with HMPV N and P, are not surprising.  If there is a greater stringency to the template 
recognition for hRSV, then it would follow that this condition is being contributed to by 
not only L but P and N as well.  As such, HMPV P and N, despite sequence homology to 
their hRSV counterparts, may not be sufficient to confer the same level of selectivity.  
This could potenitally lead to aberrant template binding and abortive RNA synthesis. 
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Subsection III:  HMPV Assembly 
 
Overall, the findings presented focus on the temporal and spatial elements that underlie a 
productive HMPV infection from RNA synthesis to egress.  One of the major results is 
that both HMPV N and P appear to move toward the plasma membrane prior to budding.  
While our work demonstrates that transient expression of HMPV P results in an 
observable concentration of the protein within filamentous processes, it is unknown 
whether these extensions are present in the cell prior to expression of the phosphoprotein.  
The data do not exclude the possibility that HMPV P could induce the formation of these 
extensions or, at least, that they form due to cellular signaling as a consequence of the 
presence of HMPV P in the cell.  However, the mechanism for such events is unclear.  
One possibility is the modulation of cytoskeletal elements, particularly those that interact 
with actin filaments.  
 
In one of these studies, association of hRSV P and F-actin was observed throughout 
infection beyond 8 hours post infection [93].  Further, the filaments could be prevented 
by either inhibition of phosphatidyl-3-kinase (PI3K) or the small GTPase Rac.  These 
results suggested that hRSV proteins were forming these filaments via signal transduction 
pathway involving PI3K and Rac.  Another report showed a role for RhoA, another small 
GTPase associated with the actin cytoskeleton, in hRSV budding [94].  In that case, it 
was formation of filamentous virions, specifically, that was affected.  Interestingly, a 
more recent study shows that an interaction between the hRSV F glycoprotein and a 
complex of N, P and M is necessary to form the viral filaments.  However, while residues 
in the cytoplasmic tail of F affected this process, it was apparent that these filaments 
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lacked F-actin, tubulin or ezrin [71].  These studies show that actin may be interacting 
with viral factors but that it is likely not the main component of the formation of hRSV 
filaments. 
 
In agreement with the work on hRSV, no detectable interaction between HMPV P and a 
selection of various focal adhesion-specific proteins, including vinculin and α-actinin, 
was found (data not shown).  This would suggest that filamentous actin is not responsible 
for the extensions observed in cells either expressing HMPV P or infected.  In the 
absence of involvement with actin or microtubules (Figures 3.17E and 3.17G), it is 
plausible that the protein itself may be able to deform membranes in such a manner as to 
cause this morphology.  If this were the case, one may also expect that HMPV P would 
be a minimal component for the formation virus-like particles; however, further study 
will be required to expand upon this finding and determine the underlying mechanism of 
this process as well as the role, if any, of filament formation in HMPV assembly.  
 
Similarly, it has yet to be determined whether or not the potential membrane blebbing 
that was observed with the co-expression of HMPV P-FLAG and the nucleocapsid 
protein was actually perturbation of the membrane in a manner consistent with formation 
of virus particles.  It has been reported that various paramyxoviral matrix proteins, alone 
or in concert with other viral factors, such as glycoproteins or the nucleocapsid, can alter 
cellular morphology and induce the formation of virus-like particles [95-101].  A finding 
that HMPV N and P can promote similar budding would be interesting as it would 
demonstrate that a combination of viral proteins can do so without the need of the matrix 
protein. 
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It is possible that, while HMPV N and P are always capable of particle formation, 
coalescence within inclusion bodies effectively secludes them from trafficking to the 
periphery.  This is supported by the observations that P-FLAG and N, while not forming 
inclusions, do interact even in instances where WT P and N do not, such as in uninfected 
cells.  Such a finding would also represent a novel association between HMPV N and P 
that is distinct from the inclusion body and the transient interaction during RNA 
synthesis. 
 
The assertion that important N-P interactions can occur outside of inclusion bodies is 
further bolstered by other data surrounding HMPV P-FLAG.  For example, the C-
terminus of the phosphoprotein has been implicated as the domain responsible for 
binding the nucleocapsid in many viruses [102-104].  In these experiments the epitope tag 
was placed at this terminus, yet the proteins are still capable of interaction (Figure 
3.13A).  Additionally, the tag did not affect the protein’s ability to concentrate within 
filamentous extensions (Figure 3.14C) or interact with the polymerase (Figure 3.12C).  
Consequently, we were unable to draw any conclusions regarding interaction between 
WT P and P-FLAG, due, in part, to differences between antibodies used in the 
immunoprecipitation.  Evidence for or against such an interaction would be significant as 
the phosphoproteins of most members in Mononegavirales are thought to take on a 
higher order structure for at least some of its function [51-52].  This, however, has not yet 
been demonstrated for HMPV.  As such, it is unclear if such an self-association would be 
necessary to retain optimal functionality.   
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The data regarding the HMPV N-P interaction, by contrast, allows for several 
conclusions to be drawn, particularly with respect to the role of inclusion bodies.  These 
structures became a central focus of these experiments, and there is mounting evidence to 
suggest that inclusions are sites of RNA synthesis for NNS viruses.  In fact, there is quite 
a  bit of support for this assertion in the case of rhabdoviruses [105-106].  The issue is 
that there is no such support for this claim for paramyxoviruses.  The results of these 
studies, in which newly-synthesized RNA mimic the observed distribution of viral 
proteins from punctate bodies to a more diffuse localization, are wholly consistent with 
the premise that inclusions are sites of viral RNA synthesis.  However, it cannot be stated 
definitively if these bodies are the sole sites of this activity, particularly beyond 12 hours 
post infection as a more diffuse distribution is then observed.  By contrast, HMPV N and 
P inclusions are still readily detected at 24hpi. 
 
One caveat of the labeling assay is that it is impossible to distinguish RNA that was 
synthesized at the beginning of the labeling period from that assembled 2 or more hours 
later.  Technically, it would be very difficult to label only during those brief periods as a 
substantial period of time is necessary to effectively starve the cells of uridine.  
Ultimately, this could mean that inclusions are strictly for the synthesis of RNA and that 
mRNA or viral genomes are moved away from these sites and nearer to the periphery of 
the cell.  Additionally, the inability to use a second probe to observe where the HMPV 
proteins associated with RNA synthesis were localized relative to the RNA was a 
limitation that does not allow for a more definitive result.  As both the RNA probe (anti-
100 
 
BrdU) and anti-HMPV antibodies were from mouse hosts, there was no way to be able to 
observe both within one experiment.  
 
Observations made in different systems may also shed light upon conserved modes of 
actions by different viruses.  In the case of HMPV, the detection of viral protein within 
filamentous extensions at later points during infection fits well with what has been 
reported for hRSV [107].  These data are consistent with the premise that HMPV utilizes 
these extensions as mode of transmission for more efficient spread of progeny viruses to 
adjacent cells.  Similar evidence has been previously reported for RSV with regard to 
filament formation likely occurring ahead of budding [108].  Though the cellular events 
involved in the formation or utilization of these structures may vary, this similarity is 
consistent with a potential overarching mechanism of viral transmission among the 
Pneumovirinae subfamily.  In such a mechanism, these processes would make cell-cell 
contacts between adjacent cells.  Therefore, the virus can utilize them as budding 
platforms, which then allows for direct orientation of progeny virus to uninfected cells.  
This would provide an efficient manner to establish productive infection within a host 
while minimizing exposure to the extracellular environment, which can lead to greater 
immune responses.  If established and characterized, this process could provide a 
potential target against which to design therapies and antiviral compounds specifically 
targeted to halting filament budding, thus inhibiting transmission. 
 
The time course studies conducted in this report demonstrate the progression of infection 
and highlight the temporal nature of specific functionalities as well.  These results are 
also consistent with a similar study on Ebola, another NNS virus [109].  It was reported 
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that Ebola inclusion bodies, containing nucleocapsid, phosphoprotein and matrix 
equivalents, move to the perinuclear space upon entry.  RNA synthesis, which began in 
these small punctate structures, expands to one side of the cell.  Viral nucleocapsids are 
then assembled and shuttle to the plasma membrane.  While there are certainly 
differences between these viruses, including the minimal constituents of the inclusion 
body, the similarities to our observations suggest that many, if not all, NNS viruses 
generally approach the tasks necessary for establishing a productive infection in a similar 
manner.  There will have to be more studies within different viral systems before more 
concrete conclusions regarding conservation of the infectious cycle of these viruses can 
be made, however. 
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Chapter V: Implications and Significance 
 
Subsection I: HMPV Fusion 
 
One of the more interesting findings from the initial mutagenesis studies was that there 
were residues in both the CBF2 region and within HRA that showed a phenotype when 
alanine was substituted for the charged side chain.  Ultimately, work with the HRA 
mutants had to be abandoned given the fact that there was no way to assess whether the 
effects of the mutation were due to modulation of triggering or an effect adoption of the 
post-fusion conformation.  These residues, particularly K166, are almost certainly 
influencing HMPV F.  In the absence of conformation-specific antibodies to HMPV F, 
one could combine the HRA mutations with those of the CBF2 region and/or H435R.  
What is most likely, however, for this theoretical K166A/D54A/E56A/H435R mutant is 
what was observed for the mutant without K166A—increased instability.  In fact, it is 
entirely possible that such a mutation would result in such a degree of instability that the 
protein would never be able to get through the secretory pathway without triggering. 
 
Thusly, there is a conundrum of studying the pH dependency of HMPV F.  One cannot 
definitively state that all regions regulating the low pH trigger of the protein have been 
identified unless a mutant is produced that is relieved of this constraint on its fusion 
activity.  However, dynamics of the metastable state of HMPV F are likely such that 
relaxing these constraints to such a degree would almost certainly result in a protein that 
would not be able to be presented on the cell surface.  Combining hyperfusogenic 
mutants from the two regions in this work led to a protein that was substantially less 
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stable.  Given that there is likely at least one other region also modulating the low pH 
dependency of the triggering of fusion, the protein with a similar mutation in this region 
would likely become all the more unstable.  From a pathogenic standpoint, metastability 
requires that a protein be able to maintain a pre-fusion form not only through the 
secretory pathway but also for some period of time on the surface of a viral particle.  For 
this reason, it is unlikely that combinatorial mutagenesis studies alone will be able to 
identify all regions responsible for regulation of HMPV F triggering. 
 
Similar to the issue of identifying further areas governing low pH triggering, 
identification of the protease that is responsible for the cleavage of HMPV F in vivo is a 
tough proposition.  The results show that a single point mutation at position 51 was 
sufficient to halt fusion activity.  Upon further study, it was found that this mutation 
altered the proteolytic processing of the protein.  What was fascinating about these results 
is that neither of the two mutations tested were at all conservative, so there is little 
evidence that can be gleaned from that aspect of the studies.   
 
Ideally, additional mutations at E51 would be synthesized, representing much less radical 
changes; these would include E51D and E51Q.  The former mutation retains the charge at 
the position but with an amino acid side chain that is one carbon shorter.  Similarly, the 
latter retains the size of the side chain without the charge.  Since, the hypothesis is that 
the less conservative mutations were sufficient to locally alter protein conformation such 
that aberrant cleavage could occur, these mutants would shed light on just what type of 
forces are responsible for the maintenance of that proper fold.  If E51D alone exhibited 
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alterations to cleavage, it would be suggestive that amino acid packing is playing a role in 
the maintenance of the structure.  Conversely, if only E51Q were aberrantly processed, it 
would suggest that charge-charge interactions are playing a role in the process.  Given the 
results of similar isosteric mutagenesis at D54 and E56, the first scenario is more 
plausible as these mutations appeared to have somewhat of a stabilizing effect.  It is also 
possible that both additional mutants would exhibit the same phenotype as the others.  In 
this case, one may need to investigate the possible role of the coordination of metal ions 
about the site, which could have a profound impact on protease activity. 
 
Another area within these studies that merits closer investigation is the potential crosstalk 
between (and/or hierarchy of) the two identified areas of HMPV F that regulate 
triggering.  The combinatorial mutagenesis study was specifically looking for a mixture 
of mutations that would allow for triggering at higher pH.  As previously discussed, this 
may not be feasible within these methods.  However, more can certainly be learned about 
the interplay between the region about H435 and the CBF2.  For example, one would test 
whether an extremely hyperfusogenic F2 mutant such as E56A would be sufficient rescue 
the phenotype of H435D/E, which had been shown to lock the prefusion form into place.  
In theory, the converse of this could also be tested, but a mutation in F2 that does not 
allow conformational change to the post-fusion has yet to be identified.  In fact, the lack 
of such a phenotype for any mutant in the F2 region suggests that H435 is dominant with 
respect to electrostatic interactions that modulate triggering. 
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The results of this work on the pH dependent triggering of HMPV F illustrate the 
complexities of regulation of HMPV fusion.  By having a single protein that can 
independently mediate fusion, the virus is dependent upon the activity of this protein 
more than others as a high error rate in replication or assembly can still theoretically lead 
to a viable pathogen.  However, if metastability is altered even slightly it can result in a 
premature triggering event or one that does not occur at all.  In either case the result is no 
infection.  Given the importance of this protein to the viral infectious cycle, it is little 
wonder that there would be multiple layers of regulation of the fusion trigger.  What is 
the most remarkable is that all of this is encoded within the primary sequence of the 
protein and how it folds.  If nothing else, these studies demonstrate the efficiency of 
HMPV and similar viruses to be able to so elegantly orchestrate the cascade of event 
necessary to enter a cell through a single protein. 
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Subsection II: HMPV Minireplicon 
 
It must be remembered that the minireplicon system created for this work was heavily 
derived from the system established by the lab of Dr. Richard Plemper with the gracious 
gift of the RSV minireplicon plasmid.  This fact must be taken into account when 
analyzing these data objectively as one may argue that these results are artifacts of the 
subcloning process and that HMPV does not truly have such a relatively low level of 
transcription.  However, the data do not support this assertion.  After every construct was 
synthesized and independently sequenced to ensure proper cloning, they were all tested 
under the same conditions with plasmids encoding the hRSV transcription machinery.  
These conditions are what likely make levels of HMPV gene expression seem 
comparatively meager.  This baseline was intentionally set up to allow for maximal signal 
from the RSV internal control in addition to the fact that the HMPV L construct had 
questionable functionality when used in the minireplicon assay, even after codon 
optimization.   
 
Further, it is plausible that the RSV RdRp has either lower binding affinity for the HMPV 
promoters.  Other data provides evidence to this end, including the fact that PIV5 L but 
not hRSV L was able to complement the loss of HMPV L.  Additionally, the HMPV 
trailer became much more active with RSV L once the TTS was added, suggesting that 
optimal promoter interaction with RSV L only occurs with that sequence at the trailer’s 
terminus.  Taken together, it is much more likely that part of the lower transcription rate 
observed in HMPV can be attributed to the enhanced selectivity of hRSV L for the TTS. 
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Another interesting finding is the ability of all tested paramyxoviruses to drive equal 
levels of transcription from a given minireplicon system and with a lower signal is lower 
than that of co-transfection of plasmids encoding the N, P and L.  The second point can 
be explained by the fact that a live virus has its own genome with which the RNA 
synthesis machinery can interact, so dampening of the signal under such conditions is 
inevitable.  The initial point, however, may be best explained by a relatively recent 
concept in the field of virology known as the quasispecies theory.  The basic idea of the 
quasispecies theory is that RNA viruses exist as hypermutable individuals within a 
cellular population, and as genetic diversity is crucial to the survival of any population in 
a given system, these individuals are not monolithic in their genomic sequences as many 
often like to think.  In addition to the consensus or base sequence that has been selected 
for over generations, genetic polymorphisms are maintained at relatively steady levels 
within a given population to allow for rapid adaptation to a changing cellular 
environment (reviewed in [33]). 
 
This theory relates to the minireplicon assay through the findings that live virus infection 
of all paramyxoviruses drove similar levels of expression.  I have already discussed the 
plausibility of the different paramyxoviral polymerases having variable selectivity for 
particular sequences at the viral promoter.  However, it is similarly plausible under 
quasispecies theory that a segment of the virus population possesses polymorphisms that 
allow for broader recognition and this minireplicon assay has actually selected for these 
individuals in the viral population.  Given the length of incubation (24 hours) during the 
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assay, this would be more than sufficient time for these individuals to induce 
transcription of the minireplicon reporter gene.  However, the more likely explanation is 
that there is simply some level of conservation with regard to paramyxoviral promoter 
binding, despite differences in the predicted RNA structures, especially given that VSV 
could not induce gene transcription at any time during these assays. 
 
This idea of paramyxoviral conservation is further bolstered by the complementation of 
HMPV N and P with PIV5 L.  Beyond the complementation itself, the fact that PIV5 L, 
either with its nucleocapsid and phosphoprotein or that of HMPV, could drive relatively 
equal rates of transcription for either the RSV or MPV promoter provides further 
evidence that the issues from the initial assays, in which the MPV plasmid seemed to be 
nearly non-functional, were likely due to the use of hRSV proteins to induce the signal.  
Under the assumption that the L protein governs the specificity of the protein-RNA 
interaction at the viral promoter during the initiation of RNA synthesis, it is likely that 
PIV5 L has a less stringent recognition motif than that hRSV L.  Further, there is only 
one region by ClustalW alignment where PIV5 L has greater sequence identity to HMPV 
L than does hRSV L (692-7[HMPV]/720-5[PIV5]), which putatively maps to conserved 
Domain III, which also contains the polymerase active site.  However, there are no 
studies that definitively demonstrate which domains of the polymerase interact with the 
viral promoter. 
 
Such a study of interactions between the RdRp and the viral promoters is just one of a 
host of future directions that this work shows as needing to be addressed.  In the case of 
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such a study, one could crosslink viral polymerases (or individually folded domains of 
each) to the RNA.  After using RNase to digest unbound RNA, sequencing of the cDNA 
would give the bound portion of the nucleic acid.  Similarly, the HMPV-PIV5 L 
complementation could be further explored through site-directed mutagenesis studies of 
the region of high conservation in Domain III followed by either the aforementioned 
binding assay or the minireplicon assay. 
 
As one can look in more detail at the contribution of the large protein to the results of 
these studies, so too can the contribution of the promoters themselves be further 
evaluated.  Given that an alteration to the trailer promoter yielded a significant change in 
measured gene transcription, one must first evaluate the contribution of both promoters to 
transcription.  In fact, it is still unclear whether the modification of the HMPV trailer 
made the construct more suited to the minireplicon assay because the trailer promoter 
itself is contributing directly to transcription of gene products or, more consistent with the 
body of work in the field, that the greater activity at the trailer promoter facilitated more 
genomic replication [89].  Increased replicase activity would, in turn, lead to more 
available genomes for transcription (Figure 1.6). 
 
There are several ways to address this question.  One of the most direct would be to 
disable the ability of the minigenome to replicate itself, while not affecting the ability to 
produce mRNA.  For HMPV, it has been reported that a transversion at the second 
position of the trailer (C2G) selectively ablates genomic replication but not gene 
transcription in a minigenome system [90].  Introduction of this mutation into the TTS 
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modified trailers could show that the enhancement observed was due to greater 
replication if this particular mutant returns to levels of expression consistent with the 
non-modified promoter.  Similarly, this contribution from the trailer can be measured by 
selectively quantifying the amount of antigenomic RNA present by either Northern 
blotting or quantitative RT-PCR.   
 
The results of these experiments have shown that there appear to be differences between 
viruses with regard to the promoter’s ability to induce gene transcription.  Additionally, 
they have shown that combinations of various viral proteins within the Paramyxoviridae 
family can functionally compensate for one another to varying degrees.  They have also 
identified a region that seems to confer specificity to the trailer promoter for the hRSV 
polymerase.  Despite these findings, major questions remain to be addressed in the 
characterization of viral promoter dynamics and their interactions with the polymerase. 
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Subsection III:  HMPV Assembly 
 
To this point I have discussed both HMPV fusion and transcription.  However, the final 
portion of the presented work may present some of the most intriguing questions with 
respect to what these very initial experiments could lead to with further study.  Among 
these exploratory findings were that HMPV P concentrates within filamentous extensions 
during the latter stages of infection but prior to detectable egress of viral particles.  There 
was also evidence to show that HMPV N coalesces in a lattice-like distribution at similar 
points post infection and that this is likely microtubule-dependent.  In addition, it was 
shown that viral RNA retains a punctate structure within the cell throughout infection 
prior to being visualized in the filamentous extension by 48 hours post infection. 
 
Moving forward from these results with the ultimate goal of identifying and targeting 
unique interactions among viral factors during HMPV infection, several experimental 
directions can be explored at the level of RNA synthesis and particle assembly.  Chief 
among such experiments should be a focus on definitive characterization of HMPV N 
and P from entry to egress.  Using the P-FLAG protein in a comparative analysis with the 
WT protein, one can conduct a controlled proteolytic digest such that the interacting 
regions of N and P or P-FLAG, P and itself or P-FLAG and P-FLAG and itself can all be 
done.  Following gel electrophoresis and mass spectrometry, regions of interaction can be 
characterized for HMPV.  The technical difficulty of this experiment would be quite 
high, but there is an alternative.  Structural analysis has been used to show such contacts 
for other viruses and can be a way forward with HMPV as well [102-103]. 
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From there, it would be most logical to next attempt to establish a cellular mechanism for 
the alteration in localization of both HMPV N and P over the course of infection.  One 
cellular factor that may be playing a role in this is Rab11, a small GTPase that typically 
localizes to recycling endosomes.  However, it is known that Rab11 can move about the 
cell on microtubules, which would explain the effect of nocodazole on HMPV N (Figure 
3.15) [110].  Checking for a direct interaction of Rab11 with HMPV N, P or P-FLAG 
would be the best manner in which to initiate these studies.  Additionally, the use of a 
dominant-negative (GDP-locked) Rab11 has been shown to mimic cytoskeletal 
disruption for elements carried by these vesicles [111].  Expression of this dominant 
negative protein in an HMPV-infected cell could be directly compared to the effects of 
nocodazole.  If HMPV N translocation is similarly affected in both cases, this would be 
evidence of a microtubule-dependent role for Rab11 in the process. 
 
While elucidation of the mechanism behind the observed translocation of HMPV N is 
interesting on its own, one would be remiss to not also attempt to link RNA synthesis to 
this process as well.  One straightforward experiment to this end would entail following 
newly synthesized RNA in cells that had been treated with nocodazole.  This would yield 
a definitive answer as to whether the HMPV nucleocapsid that is observed in a lattice-
like distribution at 12 or 24 hours post infection is primarily associated with RNA or free 
protein.  If the RNA is similarly restricted to punctate bodies following drug treatment, it 
would implicate this viral lattice as an intermediary in the transition from RNA synthesis 
to virion assembly.  Further, Rab11-postive compartments have been demonstrated to 
move influenza A viral RNA from the nucleus [112].  While HMPV RNA does not enter 
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the nucleus, its concentration at the perinuclear space early in infection suggests potential 
conservation of this mechanism. 
 
Closer examination of the interaction between HMPV N and P, would be similarly 
interesting as study N alone.  Specifically, one could assess the ability of these proteins to 
form VLPs in the absence of infection.  This is particularly interesting given the 
microscopy for co-expression of HMPV N and P-FLAG in which membrane blebs were 
visualized (Figure 3.14D-F).  If any combination of N, P and P-FLAG were sufficient for 
VLP formation, then it would also raise questions as to the function of the matrix protein, 
which is typically thought to be integral to the process for most NNS viruses [95-101].  
Even in that scenario, however, the matrix protein could still have a large role in 
organization of complete virus particle.  Moreover, one could then attempt to understand 
the underlying mechanism of this phenomenon.  For example, it may be possible to link 
the concentration of HMPV P to the filamentous extensions and VLP formation. 
 
In order to do this, however, a greater understanding of how and when the extensions are 
used by the virus must be had.  A simple interaction screen with proteins known to 
associate with focal adhesions, such as talin or RhoA, would be a start.  If any 
interactions are found, knockdowns of the interacting proteins followed by infection may 
shed light on how the virus is using the extensions.  Such a result could even spatially 
link viral assembly with particle egress. 
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As there have been technical issues visualizing HMPV RNA and HMPV proteins 
simultaneously due to antibody host limitations, one way around this would be to create 
chimeric proteins that are auto-fluorescent.  Using an mCherry fusion, for example, with 
HMPV N or P would easily allow for visualization of both protein and RNA within one 
experiment.  Such a study would be extremely informative as to where the viral proteins 
and RNA localize with respect to one another throughout HMPV infection.  Such a 
method may even allow for visualization of the large polymerase, to which there is 
currently no antibody for HMPV. 
 
The study of HMPV assembly has lagged behind other viral processes in the first decade 
since its characterization.  As more facets of this agent’s pathogenicity come to light with 
regard to fusion and entry, it will be even more crucial to be able to have an 
understanding of the subsequent steps in infection as well through continued studies like 
those proposed here.  This comprehensive characterization of HMPV biology is the only 
way to intelligently design further potential antiviral therapies. 
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Subsection IV:  Overall Implications and Significance 
 
The studies presented herein allow for a working model of the HMPV infectious cycle 
from beginning to end with new insights at several critical junctures in the process.  An 
infectious particle is likely internalized by the host cell following attachment, mediated 
by the fusion protein.  Once within the rapidly acidifying compartment, the fusion protein 
is able to sense the pH drop via a protonation event at H435.  Simultaneously, the 
hypercharged region in CBF2, containing numerous acidic amino acids, potentially have 
salt bridges disrupted.  These events, and others that we do not yet fully understand, all 
slightly alter the conformation of the metastable trimer such that it is triggered to adopt 
the postfusion form.  
 
Once the viral RNP core enters the cytosol RNA synthesis occurs, likely within inclusion 
bodies.  This transcriptive activity, which occurs largely in the perinuclear space, is 
bolstered over time by full genomic replication, allowing for greater concurrent synthesis 
of viral gene products.  Over time these viral proteins either translocate from the 
inclusion body or traffic directly to either the plasma membrane (P) or the viral lattice (N 
and P).  Gradually, HMPV P concentrates in the peripheral filamentous extensions.  
HMPV N and viral RNA are also concentrated in these areas at slightly later times.  As 
these processes extend to adjacent cells, viral budding occurs at or around 24 hours from 
initial infection, becoming more pronounced as infection progresses. 
 
The combination of the results from these studies has significantly contributed to the 
understanding of the overall pathogenesis of human metapneumovirus.  Like most other 
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emerging pathogens, HMPV has often been viewed through the prism of its similarities to 
more well-studied viruses since its characterization in 2001.  In contrast, this work sought 
to shed light on novel processes at the cellular and macromolecular level that govern 
seminal events at critical points during an infection.  To that end, this goal was 
successfully met as novel characteristics of HMPV function were found within the fusion 
protein, a necessary component of viral entry.  Further, activity of the HMPV promoters 
was assessed, and the dynamics of the major protein-protein interaction linking RNA 
synthesis to viral assembly was elucidated.  Overall, the conclusion is that while HMPV 
is similar to many viruses in many respects, it is first and foremost a uniquely interesting 
intracellular parasite that considerably deviates from the dogma of similar viruses in 
some respects while following the trend of similar viruses in others. 
 
The chief implications of these studies are that several new questions arise surrounding 
each of the areas of HMPV functionality addressed herein.  These include concerns as to 
how interrelated each of these processes truly are; for example, while the more direct 
query of what requirements are necessary to alleviate the necessity of low pH to trigger 
the fusion protein is intriguing, one must consider what effects this may have downstream 
in the process of HMPV infection.  In this instance, viral entry through an endocytic 
compartment may be favored as a means of orienting the RNP core of the particle toward 
a specific locale within the cytoplasm, such as the perinuclear space.  Further, if one 
allows that specialized carriers, such as Rab11, are involved in the trafficking of viral 
components either to the perinuclear space or away from the nucleus at later points in 
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infection, then it would logically follow that entry to the cell through such a compartment 
may spatially link this interaction with that carrier at the earliest moment possible.   
 
The best way to test this hypothesis would be via the creation of recombinant viruses.  
First one must create a virus (or VLP) presenting a different glycoprotein on its surface, 
such as PIV5 F with its attachment protein HN, that has been demonstrated to obligately 
enter at the plasma membrane.  However, all internal components should be HMPV-
specific.  One can then follow the assembly of this virus in a similar manner as described 
in these works.  Significant deviation from the observed pattern would suggest one of two 
underlying and equally interesting conclusions.  The first is that entry via endocytosis is 
necessary for proper assembly due to spatially orienting the proteins to a specific 
subcellular location.  The second, and far less likely, conclusion would be that the 
glycoprotein in its post-fusion conformation is somehow orienting the RNP to its proper 
location within the cell for optimal assembly. 
 
Just as viral entry can be theoretically linked to assembly, even greater crosstalk can be 
expected between the replication and assembly processes.  The results showed that 
HMPV P goes from a virtually exclusive localization within inclusion bodies at 6 hours 
post infection to the filamentous extensions by 12 and 24 hours.  This change in 
localization seems to occur prior to that of HMPV N or the viral RNA being visualized in 
these peripheral areas.  Given the possibility that these extensions are integral to the 
egress process for HMPV, therein is a rationale for a relatively slow transcription rate for 
HMPV.  This phenomenon may allow more time for greater viral protein accumulation 
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and, therefore, establishment of cellular egress structures (concentrated with HMPV P) 
prior to ramping up particle assembly.  This is also consistent with the observation of 
RNA throughout the infected cell only at timepoints in which some viral budding could 
be detected (24 and 48hpi).  An alternative explanation for a slow rate of transcription is 
enhanced evasion of the innate immune response.  It is also plausible that mRNA half-life 
of HMPV transcripts is much greater than that of cellular genes or even other viruses, 
such as hRSV.  
 
Finally, the unique reagents assembled throughout the course of this work lend 
themselves to studies that address interesting complex aspects of HMPV biology and 
pathogenesis.  For example, one can readily measure the ability of HMPV P-FLAG to 
drive transcription within the minireplicon system in the absence of WT P.  This would 
be informative on numerous fronts.  Primarily, it would provide evidence as to the 
necessity of inclusion bodies as replication sites since these do not form with P-FLAG 
and N, though the fact that they still interact does not rule out the possibility of RNA 
synthesis functionality remaining intact.  One can also co-express the viral proteins on 
separate plasmids and attempt to create a P-FLAG recombinant virus, which could then 
be tested in all assays from RNA synthesis to egress. 
 
Perhaps the most striking aspect of this work as a whole is not any particular result but 
rather how much is simply not known about HMPV specifically.  This virus, clinically 
relevant as it is, remains something of an enigma with the picture becoming more 
complex as each novel characteristic of its pathogenicity is revealed  To that end, these 
findings do not represent a conclusion but rather a beginning.  This work, along with that 
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of many others, is the initiation of a greater understanding of a pathogen that ultimately 
infects virtually every human on the planet and has been responsible for countless 
hospitalizations and fatalities for more than half a century. 
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